LAG-3 Antagonist Therapy for Hematological Cancers

Abstract

The present disclosure provides a method of treating a human subject suffering from a hematological cancer with a lymphocyte activation gene 3 (LAG-3) antagonist. In some embodiments, the method includes a combination of a LAG-3 antagonist and an additional therapeutic agent (e.g., a programmed death 1 pathway inhibitor). In some embodiments, the subject is about 12 years old or older and weighs about 40 kg or more, including subjects about 30 years old or younger than about 18 years old. In some embodiments, the subject weighs less than about 40 kg and / or is less than about 12 years old.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This PCT application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 273,492, filed October 29, 2021, which is incorporated by reference in its entirety herein.

[0002] The present disclosure provides methods of treating a human subject suffering from a hematological cancer comprising a lymphocyte-activation gene 3 (LAG-3) antagonist. [Background technology]

[0003] Although treatment of hematological cancers has improved over the past few decades, some patients, including those who relapse or fail first-line treatment, have poor prognosis. For example, subjects with Hodgkin's lymphoma (HL) who have residual disease prior to high-dose chemotherapy / autologous stem cell transplantation have poor long-term relapse-free survival, as do patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

[0004] There is also little consistency in the management of pediatric patients, including adolescents, with relapsed / relapsed or refractory HL or NHL, and the best approach for treating these patients has not been identified, despite the fact that these patients represent a significant proportion of patients with hematological cancers.

[0005] Thus, there is a need for improved methods for treating human subjects with hematological cancers. Summary of the Invention

[0006] The present disclosure relates to a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a lymphocyte-activation gene 3 (LAG-3) antagonist, wherein the subject is about 12 years of age or older and has a body weight of about 40 kg or greater.

[0007] The present disclosure relates to a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a LAG-3 antagonist, wherein the subject has a body weight of less than about 40 kg.

[0008] In some embodiments, the subject is less than about 30 years of age.

[0009] In some embodiments, the subject is under about 18 years of age.

[0010] In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of 60 or greater.

[0011] The present disclosure relates to a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a LAG-3 antagonist, wherein the subject is less than about 12 years of age.

[0012] In some embodiments, the subject is about 16 years of age or younger.

[0013] In some embodiments, the subject of the method who is about 16 years of age or younger has a Lansky play-performance score of 60 or greater.

[0014] In some embodiments, the method is a first line therapy.

[0015] In some embodiments, the method is a second line therapy.

[0016] In some embodiments, the method is a third line therapy.

[0017] In some embodiments, the subject has progressed on a previous therapy.

[0018] In some embodiments, the subject is naïve to a previous immuno-oncology therapy, the subject is naïve to a previous immuno-oncology therapy for a hematological cancer, or the hematological cancer is naïve to a previous immuno-oncology therapy.

[0019] In some embodiments, the LAG-3 antagonist is administered prior to high-dose chemotherapy, autologous stem cell transplant, or a combination thereof.

[0020] In some embodiments, the subject is naive to prior high-dose chemotherapy, autologous stem cell transplant, or a combination thereof.

[0021] In some embodiments, the hematological cancer is relapsed or refractory.

[0022] In some embodiments, the hematological cancer is metastatic.

[0023] In some embodiments, the hematological cancer comprises leukemia, lymphoma, or myeloma.

[0024] In some embodiments, the hematological cancer comprises Hodgkin's lymphoma.

[0025] In some embodiments, the Hodgkin's lymphoma comprises nodular lymphocyte-predominant Hodgkin's lymphoma.

[0026] In some embodiments, Hodgkin's lymphoma comprises classical Hodgkin's lymphoma.In some embodiments, classical Hodgkin's lymphoma is recurrent or refractory classical Hodgkin's lymphoma characterized by early relapse, B symptoms at relapse, extensive disease in contraindicated radiotherapy field, relapse in previous radiotherapy field, or combination thereof.In some embodiments, classical Hodgkin's lymphoma is stage IIB with bulky disease, IIIA, IIIB, or IV with E disease with or without bulky disease.

[0027] In some embodiments, hematological cancer comprises non-Hodgkin's lymphoma.In some embodiments, non-Hodgkin's lymphoma comprises diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, central nervous system lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, primary mediastinal large B-cell lymphoma, adult T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Waldenstrom's macroglobulinemia, mycosis fungoides, or Sezary syndrome. In some embodiments, non-Hodgkin's lymphoma comprises Burkitt's lymphoma, Burkitt-like lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma or anaplastic large cell lymphoma.In some embodiments, non-Hodgkin's lymphoma is relapsed or refractory non-Hodgkin's lymphoma characterized by two or more of the following: reduced performance status, high serum lactate dehydrogenase, and stage III or IV.In some embodiments, non-Hodgkin's lymphoma is stage III or IV.

[0028] In some embodiments, hematological cancers include acute myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, myeloproliferative neoplasms, systemic mastocytosis, prolymphocytic leukemia, large granular lymphocytic leukemia, or blastic plasmacytoid dendritic cell neoplasm.

[0029] In some embodiments, one or more immune cells in the tumor tissue of a subject express LAG-3. In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of immune cells express LAG-3. In some embodiments, at least about 1% of immune cells express LAG-3. In some embodiments, the immune cells are tumor-infiltrating lymphocytes. In some embodiments, the tumor-infiltrating lymphocytes are CD8 + It is a cell.

[0030] In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in a subject's tumor tissue express LAG-3. In some embodiments, at least about 1% of nucleated cells express LAG-3.

[0031] In some embodiments, one or more tumor cells in the subject's tumor tissue express PD-L1. In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of tumor cells express PD-L1. In some embodiments, at least about 1% of tumor cells express PD-L1.

[0032] In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, at least about 1% of nucleated cells express PD-L1.

[0033] In some embodiments, the LAG-3 antagonist is an anti-LAG-3 antibody.

[0034] In some embodiments, the anti-LAG-3 antibody is a full-length antibody. In some embodiments, the anti-LAG-3 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a dual-affinity re-targeting antibody (DART), a DVD-Ig, or a bispecific antibody.

[0035] In some embodiments, the anti-LAG-3 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

[0036] In some embodiments, the anti-LAG-3 antibody is selected from the group consisting of BMS-986016 (leratolimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, yelamirimab), aLAG3(0414), aLAG3(0416), Sym022, TS R-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tevotelimab), BI754111, FS118, P13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof.

[0037] In some embodiments, the anti-LAG-3 antibody comprises the CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and the CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4.

[0038] In some embodiments, the anti-LAG-3 antibody comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:5, (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:6, (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:7, (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:8, (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:9, and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:10.

[0039] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 3 and 4, respectively.

[0040] In some embodiments, the anti-LAG-3 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively.

[0041] In some embodiments, the anti-LAG-3 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs:21 and 2, respectively.

[0042] In some embodiments, the LAG-3 antagonist is a soluble LAG-3 polypeptide. In some embodiments, the soluble LAG-3 polypeptide is a fusion polypeptide. In some embodiments, the soluble LAG-3 polypeptide comprises a ligand-binding fragment of the LAG-3 extracellular domain. In some embodiments, the ligand-binding fragment of the LAG-3 extracellular domain comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity with SEQ ID NO:22. In some embodiments, the soluble LAG-3 polypeptide further comprises a half-life extending moiety. In some embodiments, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin binding polypeptide, an immunoglobulin G (IgG), an albumin binding polypeptide (ABP), a PASylation moiety, a HESylation moiety, an XTEN, a PEGylated moiety, an Fc region, or any combination thereof. In some embodiments, the soluble LAG-3 polypeptide is IMP321 (eftilagimod alpha).

[0043] In some embodiments, the LAG-3 antagonist is formulated for intravenous administration.

[0044] In some embodiments, the LAG-3 antagonist is administered in a fixed dose.

[0045] In some embodiments, the LAG-3 antagonist is at least about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, The compound is administered in a dose of about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg.

[0046] In some embodiments, the LAG-3 antagonist is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75mg, about 10mg, about 20mg, about 30mg, about 40mg, about 50mg, about 60mg, about 70mg, about 80mg, about 90mg, about 100mg, about 110mg, about 120mg, about 130mg, about 140mg, about 150mg, about 160mg, about 170mg, about 18 0mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 35 0mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 52 0mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 69 0mg, about 700mg, about 710mg, about 720mg, about 730mg, about 740mg, about 750mg, about 760mg, about 770mg, about 780mg, about 790mg, about 800mg, about 810mg, about 820mg, about 830mg, about 840mg, about 850mg, about 8 60mg, about 870mg, about 880mg, about 890mg, about 900mg, about 910mg, about 920mg, about 930mg, about 940mg, about 950mg, about 960mg, about 970mg, about 980mg, about 990mg, about 1000mg, about 1040mg, about 1080mg , about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg.

[0047] In some embodiments, the LAG-3 antagonist is administered at a weight-based dose.

[0048] In some embodiments, the LAG-3 antagonist is administered in a dose range of about 0.003 mg / kg to about 25 mg / kg, about 0.003 mg / kg to about 20 mg / kg, about 0.003 mg / kg to about 15 mg / kg, about 0.003 mg / kg to about 10 mg / kg, about 0.003 mg / kg to about 5 mg / kg, about 0.003 mg / kg to about 1 mg / kg, about 0.003 mg / kg to about 0.9 mg / kg, about 0.003 mg / kg to about 10 ... about 0.8 mg / kg, about 0.003 mg / kg to about 0.7 mg / kg, about 0.003 mg / kg to about 0.6 mg / kg, about 0.003 mg / kg to about 0.5 mg / kg, about 0.003 mg / kg to about 0.4 mg / kg, about 0.003 mg / kg to about 0.3 mg / kg, about 0.003 mg / kg to about 0.2 mg / kg, about 0.003 mg / kg to about 0.1 mg / kg, about 0.1 mg / kg to about 25 mg / kg, about 0.1 mg / kg to about 20 mg / kg, about 0.1 mg / kg to about 15 mg / kg, about 0.1 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 5 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 1 mg / kg to about 25 mg / kg, about 1 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, about 1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 5 mg / kg, about 5 mg / kg g to about 25 mg / kg, about 5 mg / kg to about 20 mg / kg, about 5 mg / kg to about 15 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 25 mg / kg, about 10 mg / kg to about 20 mg / kg, about 10 mg / kg to about 15 mg / kg, about 15 mg / kg to about 25 mg / kg, about 15 mg / kg to about 20 mg / kg, or about 20 mg / kg to about 25 mg / kg.

[0049] In some embodiments, the LAG-3 antagonist is about 0.003 mg / kg, about 0.004 mg / kg, about 0.005 mg / kg, about 0.006 mg / kg, about 0.007 mg / kg, about 0.008 mg / kg, about 0.009 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, The compound is administered at a dose of about 0.9 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 7.0 mg / kg, about 8.0 mg / kg, about 9.0 mg / kg, about 10.0 mg / kg, about 11.0 mg / kg, about 12.0 mg / kg, about 13.0 mg / kg, about 14.0 mg / kg, about 15.0 mg / kg, about 16.0 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, or about 25.0 mg / kg.

[0050] In some embodiments, the dose is administered about once every week, about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, about once every 10 weeks, about once every 11 weeks, or about once every 12 weeks.

[0051] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent. In some embodiments, the additional therapeutic agent comprises an anti-cancer agent. In some embodiments, the anti-cancer agent comprises a tyrosine kinase inhibitor, an anti-angiogenic agent, a checkpoint inhibitor, a checkpoint stimulator, a chemotherapeutic agent, an immunotherapeutic agent, a platinum agent, an alkylating agent, a taxane, a nucleoside analog, an antimetabolite, a topoisomerase inhibitor, an anthracycline, a vinca alkaloid, or any combination thereof.

[0052] In some embodiments, the tyrosine kinase inhibitor comprises afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, entrectinib, dabrafenib, trametinib, vemurafenib, larotrectinib, or any combination thereof.

[0053] In some embodiments, the antiangiogenic agent comprises an inhibitor of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), angiopoietin (Ang), tyrosine kinase with Ig-like and EGF-like domains (Tie) receptor, hepatocyte growth factor (HGF), tyrosine protein kinase Met (c-MET), C-type lectin family 14 member A (CLEC14A), multimerin 2 (MMRN2), shock protein 70-1A (HSP70-1A), epidermal growth factor (EGF), EGF receptor (EGFR), or any combination thereof.

[0054] In some embodiments, the antiangiogenic agent comprises bevacizumab, ramucirumab, aflibercept, tanibirumab, olaratumab, nesbacumab, AMG780, MEDI3617, vanucizumab, rilotumumab, ficlatuzumab, TAK-701, onartuzumab, emibetuzumab, or any combination thereof.

[0055] In some embodiments, the checkpoint inhibitor is a programmed death 1 (PD-1) pathway inhibitor, a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor, a T cell immunoglobulin and ITIM domain (TIGIT) inhibitor, a T cell immunoglobulin and mucin-domain containing molecule 3 (TIM-3) inhibitor, a TIM-1 inhibitor, a TIM-4 inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, a B and T cell lymphocyte attenuator (BTLA), a T cell immunoglobulin and mucin-domain containing molecule 3 (TIM-3) inhibitor, a TIM-1 inhibitor, a TIM-4 inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, ... attenuator inhibitors, V-domain Ig suppressor of T-cell activation (VISTA) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors, nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2) inhibitors, killer cell immunoglobulin-like receptor (KIR) inhibitors, adenosine A2a receptor (A2aR) inhibitors, transforming growth factor beta (TGF-β) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, CD47 inhibitors, CD48 inhibitors, CD73 inhibitors, CD113 inhibitors, sialic acid-binding immunoglobulin-like lectin 7 (SIGLEC-7) inhibitors, SIGLEC-9 inhibitors, SIGLEC-15 inhibitors, glucocorticoid-induced TNFR-related protein (GITR) inhibitors, galectin 1 inhibitors, galectin 9 inhibitors, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) inhibitors, G protein-coupled receptor 56 (GPR56) inhibitors, glycoprotein A repetitions predominant (GARP) inhibitors, 2B4 inhibitors, programmed death 1 homolog (PD1H) inhibitors, leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) inhibitors, or any combination thereof.

[0056] In some embodiments, the checkpoint inhibitor comprises a PD-1 pathway inhibitor.

[0057] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-1 antibody and / or an anti-PD-L1 antibody.

[0058] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-1 antibody.

[0059] In some embodiments, the anti-PD-1 antibody is a full-length antibody.

[0060] In some embodiments, the anti-PD-1 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0061] In some embodiments, the anti-PD-1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0062] In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or comprises an antigen-binding portion thereof.

[0063] In some embodiments, the anti-PD-1 antibody comprises the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14.

[0064] In some embodiments, the anti-PD-1 antibody comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 15, (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 16, (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 17, (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 18, (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 19, and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 20.

[0065] In some embodiments, the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 13 and 14, respectively.

[0066] In some embodiments, the anti-PD-1 antibody comprises a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs:11 and 12, respectively.

[0067] In some embodiments, the PD-1 pathway inhibitor is a soluble PD-L2 polypeptide. In some embodiments, the soluble PD-L2 polypeptide is a fusion polypeptide. In some embodiments, the soluble PD-L2 polypeptide comprises a ligand-binding fragment of the PD-L2 extracellular domain. In some embodiments, the soluble PD-L2 polypeptide further comprises a half-life extending moiety. In some embodiments, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin binding polypeptide, an immunoglobulin G (IgG), an albumin binding polypeptide (ABP), a PASylated moiety, a HESylated moiety, an XTEN, a PEGylated moiety, an Fc region, or any combination thereof. In some embodiments, the soluble PD-L2 polypeptide is AMP-224.

[0068] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-L1 antibody.

[0069] In some embodiments, the anti-PD-L1 antibody is a full-length antibody.

[0070] In some embodiments, the anti-PD-L1 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0071] In some embodiments, the anti-PD-L1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0072] In some embodiments, the anti-PD-L1 antibody is BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or comprises an antigen-binding portion thereof.

[0073] In some embodiments, the PD-1 pathway inhibitor is BMS-986189.

[0074] In some embodiments, the checkpoint inhibitor comprises a CTLA-4 inhibitor.

[0075] In some embodiments, the CTLA-4 inhibitor is an anti-CTLA-4 antibody.

[0076] In some embodiments, the anti-CTLA-4 antibody is a full-length antibody.

[0077] In some embodiments, the anti-CTLA-4 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0078] In some embodiments, the anti-CTLA-4 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

[0079] In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, MK-1308, AGEN-1884, or comprises an antigen-binding portion thereof.

[0080] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are formulated separately. In some embodiments, when the checkpoint inhibitor comprises multiple checkpoint inhibitors, each checkpoint inhibitor is formulated separately. In some embodiments, the checkpoint inhibitor is administered before the LAG-3 antagonist. In some embodiments, the LAG-3 antagonist is administered before the checkpoint inhibitor.

[0081] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are formulated together. In some embodiments, when the checkpoint inhibitor comprises multiple checkpoint inhibitors, two or more checkpoint inhibitors are formulated together.

[0082] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are administered simultaneously.

[0083] In some embodiments, the checkpoint inhibitor is administered in a fixed dose.

[0084] In some embodiments, the checkpoint inhibitor is at least about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about The compound is administered in a dose of from about 20 mg to about 100 mg, from about 100 mg to about 2000 mg, from about 100 mg to about 1800 mg, from about 100 mg to about 1600 mg, from about 100 mg to about 1400 mg, from about 100 mg to about 1200 mg, from about 100 mg to about 1000 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 100 mg to about 400 mg, from about 400 mg to about 2000 mg, from about 400 mg to about 1800 mg, from about 400 mg to about 1600 mg, from about 400 mg to about 1400 mg, from about 400 mg to about 1200 mg, or from about 400 mg to about 1000 mg.

[0085] In some embodiments, the checkpoint inhibitor is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75mg, about 10mg, about 20mg, about 30mg, about 40mg, about 50mg, about 60mg, about 70mg, about 80mg, about 90mg, about 100mg, about 110mg, about 120mg, about 130mg, about 140mg, about 150mg, about 160mg, about 170mg, about 18 0mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 35 0mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 52 0mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 69 0mg, about 700mg, about 710mg, about 720mg, about 730mg, about 740mg, about 750mg, about 760mg, about 770mg, about 780mg, about 790mg, about 800mg, about 810mg, about 820mg, about 830mg, about 840mg, about 850mg, about 8 60mg, about 870mg, about 880mg, about 890mg, about 900mg, about 910mg, about 920mg, about 930mg, about 940mg, about 950mg, about 960mg, about 970mg, about 980mg, about 990mg, about 1000mg, about 1040mg, about 1080mg , about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg.

[0086] In some embodiments, the checkpoint inhibitor is administered as a weight-based dose.

[0087] In some embodiments, the checkpoint inhibitor is administered in a dose range of about 0.003 mg / kg to about 25 mg / kg, about 0.003 mg / kg to about 20 mg / kg, about 0.003 mg / kg to about 15 mg / kg, about 0.003 mg / kg to about 10 mg / kg, about 0.003 mg / kg to about 5 mg / kg, about 0.003 mg / kg to about 1 mg / kg, about 0.003 mg / kg to about 0.9 mg / kg, about 0.003 mg / kg to about 0.8mg / kg, about 0.003mg / kg to about 0.7mg / kg, about 0.003mg / kg to about 0.6mg / kg, about 0.003mg / kg to about 0.5mg / kg, about 0.003mg / kg to about 0.4mg / kg, about 0.003mg / kg to about 0.3mg / kg, about 0.003mg / kg to about 0.2mg / kg, about 0.003mg / kg to about 0.1mg / kg, about 0.1mg / kg to about 25mg / kg, about 0 .1mg / kg to about 20mg / kg, about 0.1mg / kg to about 15mg / kg, about 0.1mg / kg to about 10mg / kg, about 0.1mg / kg to about 5mg / kg, about 0.1mg / kg to about 1mg / kg, about 1mg / kg to about 25mg / kg, about 1mg / kg to about 20mg / kg, about 1mg / kg to about 15mg / kg, about 1mg / kg to about 10mg / kg, about 1mg / kg to about 5mg / kg, about 5mg / kg to about 25 mg / kg, about 5 mg / kg to about 20 mg / kg, about 5 mg / kg to about 15 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 25 mg / kg, about 10 mg / kg to about 20 mg / kg, about 10 mg / kg to about 15 mg / kg, about 15 mg / kg to about 25 mg / kg, about 15 mg / kg to about 20 mg / kg, or about 20 mg / kg to about 25 mg / kg.

[0088] In some embodiments, the checkpoint inhibitor is about 0.003 mg / kg, about 0.004 mg / kg, about 0.005 mg / kg, about 0.006 mg / kg, about 0.007 mg / kg, about 0.008 mg / kg, about 0.009 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, The compound is administered at a dose of about 0.9 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 7.0 mg / kg, about 8.0 mg / kg, about 9.0 mg / kg, about 10.0 mg / kg, about 11.0 mg / kg, about 12.0 mg / kg, about 13.0 mg / kg, about 14.0 mg / kg, about 15.0 mg / kg, about 16.0 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, or about 25.0 mg / kg.

[0089] In some embodiments, the dose is administered about once every week, about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, about once every 10 weeks, about once every 11 weeks, or about once every 12 weeks.

[0090] The present disclosure relates to a method of treating a human subject with relapsed or refractory classical Hodgkin lymphoma, the method comprising administering to the subject: (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody; or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody is set forth in SEQ ID NO:3. and the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 13, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 14, and the subject is about 12 years of age or older and weighs about 40 kg or more.

[0091] In some embodiments, the subject is less than about 30 years of age.

[0092] In some embodiments, the subject is under about 18 years of age.

[0093] In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of about 60 or greater.

[0094] The present disclosure relates to a method of treating a human subject with relapsed or refractory classical Hodgkin lymphoma, the method comprising administering to the subject (a) about 2 mg / kg of an anti-LAG-3 antibody and 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and wherein the subject weighs less than about 40 kg, is less than about 12 years of age, or both.

[0095] In some embodiments, the subject is about 16 years of age or younger.

[0096] In some embodiments, the subject has a Lansky play performance score of 60 or greater.

[0097] In some embodiments, relapsed or refractory classical Hodgkin lymphoma is characterized by early relapse, B symptoms at the time of relapse, extensive disease in contraindicated radiation therapy fields, relapse in previous radiation therapy fields, or a combination thereof.

[0098] In some embodiments, the relapsed or refractory classical Hodgkin's lymphoma is stage IIB with bulky disease, IIIA, IIIB, or IV with E disease with or without bulky disease.

[0099] The present disclosure relates to a method of treating a human subject suffering from relapsed or refractory non-Hodgkin's lymphoma, the method comprising administering to the subject: (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody; or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody is set forth in SEQ ID NO:3. and the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 13, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 14, and the subject is about 12 years of age or older and weighs about 40 kg or more.

[0100] In some embodiments, the subject is less than about 30 years of age.

[0101] In some embodiments, the subject is under about 18 years of age.

[0102] In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of 60 or greater.

[0103] The present disclosure relates to a method of treating a human subject suffering from relapsed or refractory non-Hodgkin's lymphoma, the method comprising administering to the subject (a) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and the subject has a body weight of less than about 40 kg, is less than about 12 years of age, or both.

[0104] In some embodiments, the subject is about 16 years of age or younger.

[0105] In some embodiments, the subject has a Lansky play performance score of 60 or greater.

[0106] In some embodiments, relapsed or refractory non-Hodgkin's lymphoma comprises diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, central nervous system lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, primary mediastinal large B-cell lymphoma, adult T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Waldenstrom's macroglobulinemia, mycosis fungoides, or Sezary syndrome.

[0107] In some embodiments, the relapsed or refractory non-Hodgkin's lymphoma comprises Burkitt lymphoma, Burkitt-like lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, or anaplastic large cell lymphoma.

[0108] In some embodiments, the relapsed or refractory non-Hodgkin's lymphoma is characterized by two or more of: poor performance status, elevated serum lactate dehydrogenase, and stage III or IV.

[0109] In some embodiments, the relapsed or refractory non-Hodgkin's lymphoma is stage III or IV.

[0110] In some embodiments, one or more immune cells in the tumor tissue of a subject express LAG-3. In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of immune cells express LAG-3. In some embodiments, at least about 1% of immune cells express LAG-3. In some embodiments, the immune cells are tumor-infiltrating lymphocytes. In some embodiments, the tumor-infiltrating lymphocytes are CD8 + It is a cell.

[0111] In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in a subject's tumor tissue express LAG-3. In some embodiments, at least about 1% of nucleated cells express LAG-3.

[0112] In some embodiments, one or more tumor cells in the subject's tumor tissue express PD-L1. In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of tumor cells express PD-L1. In some embodiments, at least about 1% of tumor cells express PD-L1.

[0113] In some embodiments, at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, at least about 1% of nucleated cells express PD-L1.

[0114] In some embodiments, (a) the anti-LAG-3 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively; and (b) the anti-PD-1 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively.

[0115] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:13 and 14, respectively.

[0116] In some embodiments, the anti-LAG-3 antibody and / or the anti-PD-1 antibody are full-length antibodies.

[0117] In some embodiments, the anti-LAG-3 and / or anti-PD-1 antibodies are monoclonal, human, humanized, chimeric, or multispecific antibodies. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or bispecific antibody.

[0118] In some embodiments, the anti-LAG-3 antibody and / or the anti-PD-1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0119] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chains comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the sequences as set forth in SEQ ID NOs: 11 and 12, respectively.

[0120] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chains comprising the sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the sequences as set forth in SEQ ID NOs:11 and 12, respectively.

[0121] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent. In some embodiments, the additional therapeutic agent comprises an anti-cancer agent. In some embodiments, the anti-cancer agent comprises a tyrosine kinase inhibitor, an anti-angiogenic agent, a checkpoint inhibitor, a checkpoint stimulator, a chemotherapeutic agent, an immunotherapeutic agent, a platinum agent, an alkylating agent, a taxane, a nucleoside analog, an antimetabolite, a topoisomerase inhibitor, an anthracycline, a vinca alkaloid, or any combination thereof.

[0122] In some embodiments, the tyrosine kinase inhibitor comprises afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, entrectinib, dabrafenib, trametinib, vemurafenib, larotrectinib, or any combination thereof.

[0123] In some embodiments, the antiangiogenic agent comprises an inhibitor of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), angiopoietin (Ang), tyrosine kinase with Ig-like and EGF-like domains (Tie) receptor, hepatocyte growth factor (HGF), tyrosine protein kinase Met (c-MET), C-type lectin family 14 member A (CLEC14A), multimerin 2 (MMRN2), shock protein 70-1A (HSP70-1A), epidermal growth factor (EGF), EGF receptor (EGFR), or any combination thereof.

[0124] In some embodiments, the antiangiogenic agent comprises bevacizumab, ramucirumab, aflibercept, tanibirumab, olaratumab, nesbacumab, AMG780, MEDI3617, vanucizumab, rilotumumab, ficlatuzumab, TAK-701, onartuzumab, emibetuzumab, or any combination thereof.

[0125] In some embodiments, the checkpoint inhibitor is a programmed death 1 (PD-1) pathway inhibitor, a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor, a T-cell immunoglobulin and ITIM domain (TIGIT) inhibitor, a T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) inhibitor, a TIM-1 inhibitor, a TIM-4 inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, a B- and T-cell lymphocyte attenuator (BTLA) inhibitor, a V-domain Ig suppressor of T-cell activation (VISTA) inhibitor, an indoleamine 2,3-dioxygenase (IDO) inhibitor, a nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2) inhibitor, a killer cell immunoglobulin-like receptor (KIR) inhibitor, an adenosine A2a receptor (A2a R) inhibitors, transforming growth factor beta (TGF-β) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, CD47 inhibitors, CD48 inhibitors, CD73 inhibitors, CD113 inhibitors, sialic acid-binding immunoglobulin-like lectin 7 (SIGLEC-7) inhibitors, SIGLEC-9 inhibitors, SIGLEC-15 inhibitors, glucocorticoid-induced TNFR-related protein (GITR) inhibitors, galectin 1 inhibitors, galectin 9 inhibitors, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) inhibitors, G protein-coupled receptor 56 (GPR56) inhibitors, repeat-dominant glycoprotein A (GARP) inhibitors, 2B4 inhibitors, programmed death 1 homolog (PD1H) inhibitors, leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) inhibitors, or any combination thereof.

[0126] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-L1 antibody.

[0127] In some embodiments, the anti-PD-L1 antibody is a full-length antibody.

[0128] In some embodiments, the anti-PD-L1 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0129] In some embodiments, the anti-PD-L1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0130] In some embodiments, the anti-PD-L1 antibody is BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, CK-301, or comprises an antigen-binding portion thereof.

[0131] In some embodiments, the PD-1 pathway inhibitor is BMS-986189.

[0132] In some embodiments, the checkpoint inhibitor comprises a CTLA-4 inhibitor.

[0133] In some embodiments, the CTLA-4 inhibitor is an anti-CTLA-4 antibody.

[0134] In some embodiments, the anti-CTLA-4 antibody is a full-length antibody.

[0135] In some embodiments, the anti-CTLA-4 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0136] In some embodiments, the anti-CTLA-4 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

[0137] In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, MK-1308, AGEN-1884, or comprises an antigen-binding portion thereof.

[0138] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are formulated for intravenous administration.

[0139] In some embodiments, the checkpoint inhibitor is formulated for intravenous administration.

[0140] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are formulated separately. In some embodiments, the anti-PD-1 antibody is administered before the anti-LAG-3 antibody. In some embodiments, the anti-LAG-3 antibody is administered before the anti-PD-1 antibody.

[0141] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are formulated together.

[0142] In some embodiments, the LAG-3 antibody and the anti-PD-1 antibody are administered simultaneously.

[0143] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are administered about once every four weeks.

[0144] 183. The method of claim 182, wherein the anti-LAG-3 antibody and the anti-PD-1 antibody are administered on day 1 of every 4 week cycle.

[0145] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are administered intravenously from a single IV bag over a period of about 30 minutes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0146] The present disclosure provides methods of treating a human subject suffering from a hematological cancer (e.g., but not limited to, non-Hodgkin's lymphoma (NHL), or Hodgkin's lymphoma (HL), such as classical HL (cHL)), comprising administering to the subject a LAG-3 antagonist (e.g., an anti-LAG-3 antibody). In some embodiments, the subject is 12 years of age or older and weighs 40 kg or more, including subjects 30 years of age or younger or less than 18 years of age. In some embodiments, the subject weighs less than 40 kg and / or is less than 12 years of age. The present disclosure also relates to methods of treating a human subject suffering from a hematological cancer, comprising an anti-cancer therapy and / or therapeutic agent in combination with a LAG-3 antagonist, such as a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody).

[0147] I. Terminology In order that this disclosure may be more readily understood, certain terms are first defined. As used herein, unless otherwise specified herein, each of the following terms shall have the meaning set forth below. Further definitions are provided throughout this application. It should be noted that the term "a" or "an" refers to one or more of such entities. For example, "a nucleotide sequence" is understood to represent one or more nucleotide sequences. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.

[0148] The term "and / or" as used herein is to be construed as a specific disclosure of each of the two specified features or components, with or without the other. Thus, the term "and / or" used in phrases such as "A and / or B" herein is intended to include "A and B", "A or B", "A" (single), and "B" (single). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).

[0149] Whenever an embodiment is described herein using the word "comprising," it is understood that otherwise similar embodiments described using the terms "consisting of" and / or "consisting essentially of" are also provided.

[0150] The term "about" or "comprising essentially of" refers to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which error range depends in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "essentially comprising" can mean within one or more standard deviations, as is customary in the art. Alternatively, "about" or "essentially comprising" can mean a range of up to 10% or 20% (i.e., ±10% or ±20%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). Furthermore, particularly with respect to biological systems or processes, these terms can mean up to an order of magnitude or up to 5 times the value. When a specific value or composition is provided in the present application and claims, unless otherwise specified, the meaning of "about" or "essentially including" should be assumed to be within an acceptable error range for that particular value or composition.

[0151] As described herein, any concentration range, percentage range, ratio range, or integer range, unless otherwise stated, should be understood to include every integer value within the stated range, and, where appropriate, fractions thereof (e.g., 1 / 10 and 1 / 100 of an integer).

[0152] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains.For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press, The Dictionary of Cell and Molecular Biology, 5th ed., 2013, Academic Press, and Oxford Dictionary Of Biochemistry And Molecular Biology, 2006, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.

[0153] Units, prefixes, and symbols are expressed in the form accepted by the International System of Units (SI). Numeric ranges are inclusive of the numbers defining the range.

[0154] The headings provided herein are not intended to limit the various aspects of the disclosure, which can be understood by reference to the specification as a whole, and thus, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0155] As used herein, the term "hematological" may be used interchangeably with "hematologic," and hematological cancers may be referred to interchangeably as hematological malignancies.

[0156] "Antagonist" is intended to include, but is not limited to, any molecule capable of blocking, reducing, or otherwise limiting the interaction or activity of a target molecule (e.g., LAG-3). In some embodiments, the antagonist is an antibody. In other embodiments, the antagonist comprises a small molecule. The terms "antagonist" and "inhibitor" are used interchangeably herein.

[0157] "Antibody" (Ab) is intended to include, but is not limited to, a glycoprotein immunoglobulin that specifically binds an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each H chain comprises a heavy chain variable region (herein referred to as V H ) and the heavy chain constant region (abbreviated herein as C H The heavy chain constant region contains three constant domains: C H1 , C H2 and C H3 Each light chain comprises a light chain variable region (referred to herein as V L ) and a light chain constant region (abbreviated herein as C L The light chain constant region contains one constant domain, C L Includes: V H and V L The regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), between which lie more conserved regions called framework regions (FRs). H and V Lcomprises three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various immune system cells (e.g., effector cells) and the first component (C1q) of the classical complement system. The heavy chain may or may not have a C-terminal lysine. Unless otherwise specified herein, amino acids in the variable region are numbered using the Kabat numbering system and those in the constant region are numbered using the EU system.

[0158] Immunoglobulins may be derived from any of the widely known isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. IgG subclasses are also well known to those skilled in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. "Isotype" refers to the class or subclass of antibody (e.g., IgM or IgG1) encoded by the heavy chain constant region genes. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies, monoclonal and polyclonal antibodies, chimeric and humanized antibodies, human or non-human antibodies, fully synthetic antibodies, single chain antibodies, monospecific antibodies, bispecific antibodies, and multispecific antibodies. Non-human antibodies may be humanized by recombinant methods to reduce their immunogenicity in humans. Unless otherwise indicated, and unless the context dictates otherwise, the term "antibody" includes any antigen-binding fragment or portion of the aforementioned immunoglobulins, and also includes monovalent and divalent fragments or portions that retain the ability to specifically bind to the antigen bound by the intact immunoglobulin. Examples of "antigen-binding portions" or "antigen-binding fragments" include (1) Fab fragments (fragments from papain cleavage), or V L , V H , L C and C H1(2) the F(ab')2 fragment (a fragment resulting from pepsin cleavage) or the similar bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; (3) the Fd fragment consisting of the VH and CH1 domains; (4) the one-armed V L and V H (5) V H (6) Single-domain antibody (dAb) fragments consisting of two V domains connected by a hinge [Ward et al., (1989) Nature 341:544-46]; H or (7) dual variable domain immunoglobulins. In addition, the two domains of the Fv fragment, the V L and V H are encoded by separate genes, but using recombinant techniques, they can be synthesized into a single protein chain (V L and V H They can be joined by synthetic linkers that allow for the pairing of the domains to form monovalent molecules (known as single-chain Fvs (scFvs); see, e.g., Bird et al. (1988) Science 242:423-426, and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).

[0159] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds to LAG-3 is substantially free of antibodies that do not specifically bind to LAG-3). However, an isolated antibody that specifically binds to LAG-3 may have cross-reactivity with other antigens, such as LAG-3 molecules from different species. In addition, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0160] The term "monoclonal antibody" ("mAb") refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., antibody molecules which are essentially identical in primary sequence and which display a single binding specificity and affinity for a particular epitope. A mAb is an example of an isolated antibody. mAbs can be produced by hybridoma, recombinant, transgenic, or other techniques known to those of skill in the art.

[0161] A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from a human germline immunoglobulin sequence. The human antibodies of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or in vivo somatic mutation). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibody and "fully human" antibody are used interchangeably.

[0162] "Humanized antibody" refers to an antibody in which some, most, or all of the amino acids outside the CDR domain of a non-human antibody are replaced with the corresponding amino acids from a human immunoglobulin. In one embodiment of a humanized antibody, some, most, or all of the amino acids outside the CDR domain are replaced with amino acids from a human immunoglobulin, while some, most, or all of the amino acids in one or more CDR regions remain unchanged. Small additions, deletions, insertions, substitutions, or modifications of amino acids are acceptable as long as they do not eliminate the ability of the antibody to bind to a specific antigen. A "humanized" antibody retains antigen specificity similar to that of the original antibody.

[0163] A "chimeric antibody" refers to an antibody in which the variable region is derived from one species and the constant region is derived from another species, e.g., the variable region is derived from a murine antibody and the constant region is derived from a human antibody.

[0164] An "anti-antigen" antibody refers to an antibody that specifically binds to an antigen. For example, an anti-LAG-3 antibody specifically binds to LAG-3.

[0165] "LAG-3" refers to lymphocyte activation gene 3. The term "LAG-3" includes variants, isoforms, homologs, orthologs, and paralogs. For example, an antibody specific for human LAG-3 protein may cross-react with LAG-3 protein from species other than human in some cases. In other embodiments, an antibody specific for human LAG-3 protein may be completely specific for human LAG-3 protein and may not exhibit species or other types of cross-reactivity, or may cross-react with LAG-3 from other specific species but not with LAG-3 from all other species (e.g., cross-react with monkey LAG-3 but not with mouse LAG-3). The term "human LAG-3" refers to human sequence LAG-3, such as the complete amino acid sequence of human LAG-3 with GenBank accession number NP_002277. The term "mouse LAG-3" refers to mouse sequence LAG-3, such as the complete amino acid sequence of mouse LAG-3 with GenBank accession number NP_032505. LAG-3 is also known in the art as, for example, CD223. A human LAG-3 sequence may differ from human LAG-3 of GenBank Accession No. NP_002277, for example, by having a conserved mutation or a mutation in a non-conserved region, and the LAG-3 has substantially the same biological function as human LAG-3 of GenBank Accession No. NP_002277. For example, the biological function of human LAG-3 is to have an epitope within the extracellular domain of LAG-3 to which an antibody of the present disclosure specifically binds, or the biological function of human LAG-3 is to bind to an MHC class II molecule.

[0166] A particular human LAG-3 sequence is generally at least about 90% identical in amino acid sequence to the human LAG-3 of GenBank Accession No. NP_002277 and contains amino acid residues that identify the amino acid sequence as human when compared to the LAG-3 amino acid sequence of other species (e.g., mouse). Optionally, the human LAG-3 can be at least about 95% identical in amino acid sequence to the LAG-3 of GenBank Accession No. NP_002277, or even at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical. In certain embodiments, the human LAG-3 sequence shows 10 or fewer amino acid differences with the LAG-3 sequence of GenBank Accession No. NP_002277. In certain embodiments, human LAG-3 may display no more than 5, or even no more than 4, no more than 3, no more than 2, or no more than 1 amino acid difference from the LAG-3 sequence of GenBank Accession No. NP_002277.

[0167] "Programmed Death 1 (PD-1)" refers to an immune inhibitory receptor belonging to the CD28 family. PD-1 is expressed primarily in T cells previously activated in vivo and binds to two ligands, PD-L1 and PD-L2. As used herein, the term "PD-1" includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs that share at least one epitope in common with hPD-1. The complete hPD-1 sequence can be found in GenBank Accession No. U64863. "PD-1" and "PD-1 receptor" are used interchangeably herein.

[0168] "Cytotoxic T-lymphocyte antigen 4 (CTLA-4)" refers to an immunoinhibitory receptor belonging to the CD28 family. In vivo, CTLA-4 is expressed exclusively in T cells and binds to two ligands, CD80 and CD86 (also called B7-1 and B7-2, respectively). As used herein, the term "CTLA-4" includes human CTLA-4 (hCTLA-4), variants, isoforms, and species homologs of hCTLA-4, and analogs that share at least one epitope with hCTLA-4. The complete hCTLA-4 sequence can be found in GenBank accession number AAB59385.

[0169] "Programmed death-ligand-1 (PD-L1)" is one of two cell surface glycoprotein ligands for PD-1 (the other is PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1. As used herein, the term "PD-L1" includes human PD-L1 (hPD-L1), variants, isoforms, and species homologs of hPD-L1, and analogs that share at least one epitope in common with hPD-L1. The complete hPD-L1 sequence can be found at GenBank Accession No. Q9NZQ7.

[0170] As used herein, "programmed death-ligand-2 (PD-L2)" includes human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs that share at least one epitope in common with hPD-L2. The complete hPD-L2 sequence can be found in GenBank Accession No. Q9BQ51.

[0171] As used herein, a "patient" includes any patient suffering from a hematological cancer (e.g., Hodgkin's lymphoma or non-Hodgkin's lymphoma). The terms "subject" and "patient" are used interchangeably herein.

[0172] "Administering" refers to the physical introduction of a therapeutic agent (e.g., a composition or formulation comprising a therapeutic agent) to a subject using any of a variety of methods and delivery systems known to those skilled in the art. Exemplary routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, for example, by injection or infusion. As used herein, the phrase "parenteral administration" refers to forms of administration, usually by injection, excluding enteral and topical administration, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion, and in vivo electroporation. The formulation is administered by a non-parenteral route in some embodiments, and orally in some embodiments. Other non-parenteral routes include topical, epithelial, or mucosal routes of administration, for example, intranasal, vaginal, rectal, sublingual, or topical. Administration can be, for example, once, multiple times, and / or over one or more extended periods of time.

[0173] "Treatment" or "therapy" of a subject refers to any kind of intervention or process performed on a subject, or administration of an active agent to a subject, with the aim of reversing, mitigating, ameliorating, arresting, slowing the progression, occurrence, severity, or recurrence of symptoms, complications, or pathology, or biochemical signs associated with a disease. RECIST (Response Evaluation Criteria In Solid Tumors) is a measure of treatment efficacy and is an established rule that defines when a tumor responds, stabilizes, or progresses during treatment. RECIST 1.1 is the current guideline for defining the objective evaluation of changes in measurement and tumor size of solid tumors used in adult and pediatric cancer clinical trials.

[0174] As used herein, "effective treatment" refers to a treatment that produces a beneficial effect, e.g., an improvement in at least one symptom of a disease or disorder. A beneficial effect can take the form of an improvement compared to baseline, i.e., an improvement compared to measurements or observations made before starting therapy according to the subject method. A beneficial effect can also take the form of preventing, slowing, decelerating, or stabilizing the adverse progression of markers of solid tumors. Effective treatment can refer to the alleviation of at least one symptom of solid tumors. Such effective treatment can, for example, reduce the patient's pain, reduce the size and / or number of lesions, reduce or prevent tumor metastasis, and / or slow the growth of tumors.

[0175] The term "effective amount" refers to the amount of an agent that produces a desired biological, therapeutic, and / or preventive result. This result may be reduction, amelioration, remission, relief, delay, and / or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. With respect to solid tumors, an effective amount includes an amount sufficient to shrink the tumor and / or reduce the growth rate of the tumor (e.g., inhibit tumor growth), or slow other unwanted cell proliferation. In some embodiments, an effective amount is an amount sufficient to prevent or delay tumor recurrence. An effective amount may be administered in one or more administrations. An effective amount of a drug or composition can (i) reduce the number of cancer cells, (ii) reduce tumor size, (iii) inhibit, slow, partially slow, and stop the invasion of cancer cells into peripheral organs, (iv) inhibit (i.e., partially slow and stop) tumor metastasis, (v) inhibit tumor growth, (vi) prevent or delay the onset and / or recurrence of tumors, and / or (vii) alleviate to some extent one or more symptoms associated with cancer. In one example, an "effective amount" is an amount of anti-LAG-3 antibody alone, or an amount of anti-LAG-3 antibody in combination with an amount of an additional therapeutic agent (e.g., an anti-PD-1 antibody), that has been clinically proven to result in a significant reduction in cancer, such as advanced solid tumors, or a slowing of cancer progression.

[0176] As used herein, the terms "fixed dose", "constant dose" and "constant fixed dose" are used interchangeably and refer to a dose administered to a patient regardless of the patient's weight or body surface area (BSA). Thus, a fixed dose or constant dose is provided as an absolute amount of drug (e.g., a dose in μg or mg) rather than as a mg / kg dose.

[0177] The use of the term "fixed dose combination" with respect to the compositions of the invention means that two or more different inhibitors described herein (e.g., anti-LAG-3 antibody and anti-PD-1 antibody) in a single composition are present in the composition in a specific (fixed) ratio relative to each other. In some embodiments, the fixed dose is based on the weight (e.g., mg) of the inhibitor. In certain embodiments, the fixed dose is based on the concentration (e.g., mg / ml) of the inhibitor. In some embodiments, the ratio is at least about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200 , about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, or about 2:1 (mg of first inhibitor:mg of second inhibitor). For example, a 3:1 ratio of first inhibitor and second inhibitor can mean that a vial can contain about 480 mg of first inhibitor and 160 mg of second inhibitor or about 6 mg / ml of first inhibitor and 2 mg / ml of second inhibitor.

[0178] The term "body weight dose" referred to herein means that the dose administered to a patient is calculated based on the patient's body weight.

[0179] As used herein, "dosing interval" refers to the amount of time that elapses between multiple administrations of the formulations disclosed herein to a subject. Thus, the dosing interval can be expressed as a range.

[0180] The term "dosing frequency" as used herein refers to the frequency of administering a dose of the formulation disclosed herein within a given time period.Dosing frequency can be indicated as the number of doses per given time period, for example, once a week or once every two weeks.

[0181] As used herein, the terms "about once a week," "about once every week," "about once every 2 weeks," or other similar dosing interval terms refer to approximate numbers, and "about once a week" or "about once every week" can include every 7 days ± 2 days, i.e., every 5 days to every 9 days. Thus, the dosing frequency of "once a week" can be every 5 days, every 6 days, every 7 days, every 8 days, or every 9 days. "About once every 3 weeks" can include every 28 days ± 3 days, i.e., every 25 days to every 31 days. Similar approximations apply, for example, to about once every 2 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, about once every 10 weeks, about once every 11 weeks, and about once every 12 weeks. In some embodiments, a dosing interval of about once every 6 weeks or about once every 12 weeks means that the first dose can be administered on any day during week 1, and then the next dose can be administered on any day during week 6 or week 12, respectively. In other embodiments, a dosing interval of about once every 6 weeks or about once every 12 weeks means that the first dose is administered on a particular day (e.g., a Monday) during week 1, and then the next dose is administered on the same day (i.e., a Monday) during week 6 or week 12, respectively.

[0182] As used herein, an "adverse event" (AE) is an unfavorable and generally unintended or undesirable sign (including abnormal laboratory findings), symptom, or disease associated with the use of a medical treatment.For example, an adverse event may be associated with the activation of the immune system or the expansion of immune system cells (e.g., T cells) in response to the treatment.A medical treatment may have one or more associated AEs, and each AE may have the same or different levels of severity.

[0183] As used herein, the term "tumor" refers to a mass of tissue resulting from excessive cell growth or proliferation, whether benign (non-cancerous) or malignant (cancerous), including pre-cancerous lesions.

[0184] The term "biological sample" as used herein refers to biological material isolated from a subject. Biological sample may contain any biological material suitable for analysis, for example, by sequencing nucleic acid in tumor (or circulating tumor cells) and identifying genomic alterations in the sequenced nucleic acid. Biological sample may be any suitable biological tissue or fluid, for example, tumor tissue, blood, plasma, and serum. Biological sample may be a test tissue sample (for example, a tissue sample that contains tumor cells and tumor-infiltrating inflammatory cells). In one embodiment, the sample is a tumor tissue biopsy, for example, formalin-fixed paraffin-embedded (FFPE) tumor tissue or fresh frozen tumor tissue. In another embodiment, the biological sample is a liquid biopsy, which in some embodiments includes one or more of blood, serum, plasma, circulating tumor cells, exoRNA, ctDNA, and cfDNA.

[0185] As an example, an "anti-cancer agent" promotes the regression of cancer in a subject. In a preferred embodiment, a therapeutically effective amount of the agent promotes the regression of cancer to the point of eliminating the cancer. "Promoting the regression of cancer" means that administering an effective amount of an anti-cancer agent, alone or in combination with another agent, results in a reduction in tumor growth or size, tumor necrosis, a decrease in the severity of at least one disease symptom, an increase in the frequency and duration of disease-free periods, or prevention of functional impairment or disability due to the affliction. Furthermore, the terms "effective" and "efficacy" in relation to treatment include both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of an agent to promote the regression of cancer in a patient. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse effects) at the cell, organ, and / or organism level resulting from the administration of the agent.

[0186] As an example for tumor treatment, a therapeutically effective amount of an anticancer agent can inhibit cell growth or tumor growth by at least about 20%, at least about 40%, at least about 60%, or at least about 80% compared to untreated subjects. In other embodiments of the present disclosure, tumor regression can be observed and sustained for at least about 20 days, more preferably at least about 40 days, or at least about 60 days. Regardless of these therapeutic efficacy measurements, the evaluation of immunotherapeutic agents must also take into account immune-related response patterns.

[0187] As used herein, "immuno-oncology" therapy or "IO" or "IO" therapy refers to a therapy that involves utilizing immune response to target and treat tumors in a subject. Thus, as used herein, IO therapy is a type of anti-cancer therapy. In some embodiments, IO therapy includes administering an antibody to a subject. In some embodiments, IO therapy includes administering an immune cell, such as a T cell, such as a modified T cell, such as a T cell modified to express a chimeric antigen receptor or a specific T cell receptor, to a subject. In some embodiments, IO therapy includes administering a therapeutic vaccine to a subject. In some embodiments, IO therapy includes administering a cytokine or chemokine to a subject. In some embodiments, IO therapy includes administering an interleukin to a subject. In some embodiments, IO therapy includes administering an interferon to a subject. In some embodiments, IO therapy includes administering a colony-stimulating factor to a subject.

[0188] "Immune response" refers to the actions of cells of the immune system (e.g., T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils), and soluble macromolecules (including antibodies, cytokines, and complement) produced by any of these cells or by the liver, that result in the selective targeting, binding to, damaging, destroying, and / or elimination from the vertebrate body of invading pathogens, pathogen-infected cells or tissues, cancerous or other abnormal cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.

[0189] "Tumor-infiltrating inflammatory cells" or "tumor-associated inflammatory cells" are any type of cell that typically participates in an inflammatory response in a subject and infiltrates tumor tissue. Such cells include tumor-infiltrating lymphocytes (TILs), macrophages, monocytes, eosinophils, histiocytes, and dendritic cells.

[0190] The term "LAG-3 positive" or "positive LAG-3 expression" with respect to LAG-3 expression refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing LAG-3 based on the proportion (i.e., percentage) of immune cells (e.g., tumor infiltrating lymphocytes such as CD8+ T cells) that express LAG-3 (e.g., expression of 1% or more) or the proportion (i.e., percentage) of nucleated cells that express LAG-3 (i.e., immune cells that express LAG-3 as a percentage of total nucleated cells, e.g., expression of 1% or more).

[0191] "LAG-3 negative" or "negative for LAG-3 expression" refers to a tumor tissue (e.g., a test tissue sample) that is not scored as expressing LAG-3 (e.g., LAG-3 expression is less than 1%).

[0192] The term "PD-1 positive" or "positive PD-1 expression" with respect to PD-1 expression refers to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-1 based on the proportion (i.e., percentage) of immune cells (e.g., tumor infiltrating lymphocytes such as CD8+ T cells) that express PD-1 (e.g., expression of 1% or greater) or the proportion (i.e., percentage) of nucleated cells that express PD-1 (i.e., immune cells that express PD-1 as a percentage of total nucleated cells, e.g., expression of 1% or greater).

[0193] "PD-1 negative" or "PD-1 expression negative" refers to a tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-1 (e.g., PD-1 expression is less than 1%).

[0194] The terms "PD-L1 positive" or "positive PD-L1 expression" with respect to cell surface PD-L1 expression refer to tumor tissue (e.g., a test tissue sample) that is scored as expressing PD-L1 based on the proportion (i.e., percentage) of tumor cells that express PD-L1 (e.g., expression of 1% or greater) or the proportion (i.e., percentage) of nucleated cells that express PD-L1 (i.e., tumor cells that express PD-L1 as a percentage of total nucleated cells, e.g., expression of 1% or greater).

[0195] The terms "PD-L1 negative" or "PD-L1 expression negative" refer to a tumor tissue (e.g., a test tissue sample) that is not scored as expressing PD-L1 (e.g., expression is less than 1%).

[0196] Various aspects of the invention are described in further detail in the following subsections.

[0197] II. Methods of the Disclosure Provided herein is a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a LAG-3 antagonist (e.g., an anti-LAG-3 antibody), alone or in combination with one or more additional therapeutic agents (e.g., a PD-1 pathway inhibitor such as an anti-PD-1 antibody), wherein the subject is about 12 years of age or older and has a body weight of about 40 kg or greater.

[0198] In some embodiments, the subject is about 100 years of age or less, about 95 years of age or less, about 90 years of age or less, about 85 years of age or less, about 80 years of age or less, about 75 years of age or less, about 70 years of age or less, about 65 years of age or less, about 60 years of age or less, about 55 years of age or less, about 50 years of age or less, about 45 years of age or less, about 40 years of age or less, about 35 years of age or less, about 30 years of age or less, about 25 years of age or less, about 20 years of age or less, about 19 years of age or less, about 18 years of age or less, about 17 years of age or less, about 16 years of age or less, about 15 years of age or less, about 14 years of age or less, or about 13 years of age or less.

[0199] In some embodiments, the subject is an adolescent or young adult.

[0200] In some embodiments, the subject is from about 15 years of age or older, about 20 years of age or older, about 25 years of age or older, about 30 years of age or older, about 35 years of age or older, about 40 years of age or older, about 45 years of age or older, or about 50 years of age or older to about 100 years of age or younger, about 95 years of age or younger, about 90 years of age or younger, about 85 years of age or younger, about 80 years of age or younger, about 75 years of age or younger, about 70 years of age or younger, about 65 years of age or younger, or about 60 years of age or younger (e.g., from about 15 years of age or older to about 35 years of age or younger, from about 15 years of age or older to about 20 years of age or younger, or from about 50 years of age or older to about 60 years of age or younger).

[0201] In some embodiments, the subject has a weight of about 45 kg or more, about 50 kg or more, about 55 kg or more, about 60 kg or more, about 65 kg or more, about 70 kg or more, about 75 kg or more, about 80 kg or more, about 85 kg or more, about 90 kg or more, about 95 kg or more, about 100 kg or more, about 110 kg or more, about 120 kg or more, about 130 kg or more, about 140 kg or more, or about 150 kg or more.

[0202] Provided herein is a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a LAG-3 antagonist (e.g., an anti-LAG-3 antibody), alone or in combination with one or more additional therapeutic agents (e.g., a PD-1 pathway inhibitor such as an anti-PD-1 antibody), wherein the subject has a body weight of less than 40 kg.

[0203] In some embodiments, the subject is about 100 years of age or less, about 95 years of age or less, about 90 years of age or less, about 85 years of age or less, about 80 years of age or less, about 75 years of age or less, about 70 years of age or less, about 65 years of age or less, about 60 years of age or less, about 55 years of age or less, about 50 years of age or less, about 45 years of age or less, about 40 years of age or less, about 35 years of age or less, about 30 years of age or less, about 25 years of age or less, about 20 years of age or less, about 19 years of age or less, about 18 years of age or less, about 17 years of age or less, about 16 years of age or less, about 15 years of age or less, about 14 years of age or less, about 13 years of age or less, about 12 years of age or less, about 10 years of age or less, about 9 years of age or less, about 8 years of age or less, about 7 years of age or less, about 6 years of age or less, about 5 years of age or less, about 4 years of age or less, about 3 years of age or less, about 2 years of age or less, or about 1 year of age or less.

[0204] In some embodiments, the subject is about 12 months or younger, about 11 months or younger, about 10 months or younger, about 9 months or younger, about 8 months or younger, about 7 months or younger, or about 6 months or younger.

[0205] In some embodiments, the subject is a neonate, infant, child, adolescent, or young adult.

[0206] In some embodiments, the subject is from about 1 year or older, about 2 years or older, about 3 years or older, about 4 years or older, about 5 years or older, about 6 years or older, about 7 years or older, about 8 years or older, about 9 years or older, or about 10 years or older to about 100 years or younger, about 95 years or younger, about 90 years or younger, about 85 years or younger, about 80 years or younger, about 75 years or younger, about 70 years or younger, about 65 years or younger, about 60 years or younger, about 55 years or younger, about 50 years or younger, about 45 years or younger, about 40 years or younger, about 35 years or younger, about 30 years or younger, about 25 years or younger, about 20 years or younger, about 19 years or younger, about 18 years or younger, about 17 years or younger, about 16 years or younger, about 15 years or younger, about 14 years or younger, about 13 years or younger, about 12 years or younger, or about 11 years or younger (e.g., from about 5 years or older to about 15 years or younger).

[0207] In some embodiments, the subject is from about 10 years or older, about 11 years or older, about 12 years or older, about 13 years or older, about 14 years or older, or about 15 years or older to about 100 years or younger, about 95 years or younger, about 90 years or younger, about 85 years or younger, about 80 years or younger, about 75 years or younger, about 70 years or younger, about 65 years or younger, about 60 years or younger, about 55 years or younger, about 50 years or younger, about 45 years or younger, about 40 years or younger, about 35 years or younger, about 30 years or younger, about 25 years or younger, about 20 years or younger, about 19 years or younger, about 18 years or younger, about 17 years or younger, or about 16 years or younger (e.g., from about 15 years or older to about 35 years or younger, from about 15 years or older to about 20 years or younger, or from about 50 years or older to about 60 years or younger).

[0208] In some embodiments, the subject has a weight of about 35 kg or less, about 30 kg or less, about 25 kg or less, about 20 kg or less, about 15 kg or less, about 10 kg or less, or about 5 kg or less.

[0209] Provided herein is a method of treating a human subject suffering from a hematological cancer, the method comprising administering to the subject a LAG-3 antagonist (e.g., an anti-LAG-3 antibody), alone or in combination with one or more additional therapeutic agents (e.g., a PD-1 pathway inhibitor such as an anti-PD-1 antibody), and the subject is under the age of 12.

[0210] In some embodiments, the subject is 11 or younger, 10 or younger, 9 or younger, 8 or younger, 7 or younger, 6 or younger, 5 or younger, 4 or younger, 3 or younger, 2 or younger, or 1 or younger.

[0211] In some embodiments, the subject is about 12 months or younger, about 11 months or younger, about 10 months or younger, about 9 months or younger, about 8 months or younger, about 7 months or younger, or about 6 months or younger.

[0212] In some embodiments, the subject is a neonate, infant, or child.

[0213] In some embodiments, the methods of the disclosure include administering a LAG-3 antagonist (e.g., an anti-LAG-3 antibody, alone or in combination with one or more additional therapeutic agents (e.g., a PD-1 pathway inhibitor, such as an anti-PD-1 antibody)) to a subject based on the subject's performance status. Performance status can be indicated by any one or more systems in the art.

[0214] In some embodiments, performance status is indicated by Karnofsky performance status, Lansky play performance status, and / or Eastern Cooperative Oncology Group performance status (ECOG PS), which use standardized criteria to measure how a disease affects a patient's ability to perform daily activities.

[0215] The criteria for scoring the Karnofsky Performance Status and the Lansky Play Performance Status are shown in Table 1. The Karnofsky Performance Status can be determined, for example, for subjects over the age of 16, while the Lansky Play Performance Status can be determined, for example, for subjects under the age of 16. Table 1: Karnofsky and Lansky criteria [Table 1]

[0216] In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of 10 or greater, 20 or greater, 30 or greater, 40 or greater, 50 or greater, 60 or greater, 70 or greater, 80 or greater, or 90 or greater. In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of 100.

[0217] In some embodiments, the subject is about 16 years of age or younger and has a Lansky play performance score of 10 or greater, 20 or greater, 30 or greater, 40 or greater, 50 or greater, 60 or greater, 70 or greater, 80 or greater, or greater than 90. In some embodiments, the subject has a Lansky play performance score of 100.

[0218] Example definitions of ECOG PS include: "0": fully active, able to perform all pre-disease performance without limitation, "1": limited physically strenuous activity but ambulatory and able to perform light or sedentary tasks, "2": ambulatory, able to perform full self-care and mobile >50% of waking time but unable to perform any work activities, "3": able to perform only limited self-care and confined to a bed or chair >50% of waking time, and "4": completely immobile, unable to care for themselves at all, and unable to leave a bed or chair at all.

[0219] In some embodiments, the subject has an ECOG PS of 4 or less, 3 or less, 2 or less, or 1 or less.

[0220] In some embodiments, the method is a first-line (1L) therapy.

[0221] In some embodiments, the method is a second line (2L) therapy.

[0222] In some embodiments, the method is a third line (3L) therapy.

[0223] In some embodiments, the subject has progressed on a previous therapy.

[0224] In some embodiments, the subject has not received prior systemic therapy for cancer, the subject has not received prior systemic therapy for hematological cancer, or the subject has not received prior systemic therapy for advanced or metastatic hematological cancer.

[0225] In some embodiments, the subject is naive to previous immuno-oncology (IO) therapy. In some embodiments, the subject has never received IO therapy, has received IO therapy for cancer other than hematological cancer, or has received IO therapy for past hematological cancer but not for current hematological cancer. In some embodiments, the subject is naive to previous IO therapy, the subject is naive to previous IO therapy for hematological cancer, or the hematological cancer is naive to previous IO therapy. In some embodiments, the previous IO therapy is an antibody. In some embodiments, the antibody binds to a checkpoint inhibitor. In some embodiments, the previous IO therapy is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or a combination thereof.

[0226] In some embodiments, the LAG-3 antagonist (e.g., an anti-LAG-3 antibody, alone or in combination with one or more additional therapeutic agents (e.g., a PD-1 pathway inhibitor such as an anti-PD-1 antibody)) is administered prior to high-dose chemotherapy (HDCT), autologous stem cell transplant (ASCT), or a combination thereof.

[0227] In some embodiments, the subject is naive to prior HDCT, ASCT, or a combination thereof.

[0228] In some embodiments, the hematological cancer is unresectable, advanced, recurrent, refractory, and / or metastatic.

[0229] In some embodiments, the hematological cancer is relapsed or refractory.

[0230] In some embodiments, the hematological cancer is metastatic.

[0231] In some embodiments, the hematological cancer comprises leukemia, lymphoma, or myeloma.

[0232] In some embodiments, the hematological cancer comprises B cell lymphoma (eg, mature B cell lymphoma), T cell lymphoma, or natural killer cell lymphoma.

[0233] In some embodiments, the hematological cancer comprises Hodgkin's lymphoma.

[0234] Hodgkin's lymphoma (HL) has a bimodal age distribution with peak incidence between 15 and 34 years and again between 50 and 60 years. A significant proportion of cases occur in the pediatric age group, with the majority appearing in adolescents, and a small number of cases presenting in patients younger than 10 years of age.

[0235] In some embodiments, the Hodgkin's lymphoma comprises nodular lymphocyte-predominant Hodgkin's lymphoma.

[0236] In some embodiments, Hodgkin's lymphoma comprises classical Hodgkin's lymphoma (cHL). cHL can be characterized by rare malignant Reed-Sternberg cells surrounded by a widespread but ineffective inflammatory immune cell infiltrate.

[0237] In some embodiments, the cHL comprises nodular sclerosing Hodgkin lymphoma, mixed cellularity Hodgkin lymphoma, lymphocyte-reduced Hodgkin lymphoma, or lymphocyte-rich classical Hodgkin lymphoma.

[0238] In some embodiments, the cHL is relapsed or refractory cHL characterized by early relapse, B symptoms at relapse, extensive disease in contraindicated radiation therapy fields, relapse in previous radiation therapy fields, or a combination thereof.

[0239] In some embodiments, the cHL is staged according to the Lugano 2014 classification. See, e.g., Cheson et al., J. Clin. Oncol. 32(27):3059-3067 (2014).

[0240] In some embodiments, the cHL is stage IIB with bulky disease, IIIA, IIIB, or IV with E-lesions with or without bulky disease, where E-lesions are defined as local involvement of extranodal tissues (by contiguous growth from or in close anatomical relationship to an involved lymph node) that is treatable by radiation.

[0241] In some embodiments, the hematological cancer comprises non-Hodgkin's lymphoma (NHL).

[0242] In some embodiments, NHL comprises diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, central nervous system lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, primary mediastinal large B-cell lymphoma, adult T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Waldenstrom's macroglobulinemia, mycosis fungoides, or Sezary syndrome.

[0243] NHL accounts for 10%-12% of cancers and nearly two-thirds of lymphomas diagnosed in children. Approximately 70% of children with NHL present with advanced disease and / or have metastatic involvement involving the bone marrow, central nervous system (CNS), and / or bone, in contrast to adult NHL, which tends to present as lower intermediate grade. Childhood and adolescent NHL is divided into three main histological categories: mature B-cell [Burkitt and Burkitt-like lymphomas (30%) and diffuse large B-cell lymphoma (DLBCL; 10-20%)], lymphoblastic lymphoma (20%), and anaplastic large cell lymphoma (10%). Childhood NHL occurs most commonly in the teenage years of life and less frequently before age 3. In children, NHL consists primarily of mature, aggressive B-cell lymphomas, with Burkitt lymphoma being the most common in those aged 5-14 years and DLBCL predominating in those aged 15-19 years.

[0244] In some embodiments, the NHL comprises Burkitt lymphoma, Burkitt-like lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, or anaplastic large cell lymphoma.

[0245] In some embodiments, the NHL is recurrent or refractory NHL characterized by two or more of the following: poor performance status, high serum lactate dehydrogenase, and stage III or IV.In some embodiments, the NHL is staged according to the Lugano 2014 classification.

[0246] In some embodiments, the subject is over about 16 years of age and has a Karnofsky performance score of 80 or less, 70 or less, 60 or less, 50 or less, 40 or less, 30 or less, or 20 or less.

[0247] In some embodiments, the subject is about 16 years of age or younger and has a Lansky play performance score of 80 or less, 70 or less, 60 or less, 50 or less, 40 or less, 30 or less, or 20 or less.

[0248] In some embodiments, the NHL is stage III or IV.

[0249] In some embodiments, hematological cancers include acute myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, myeloproliferative neoplasms, systemic mastocytosis, prolymphocytic leukemia, large granular lymphocytic leukemia, or blastic plasmacytoid dendritic cell neoplasm.

[0250] In some embodiments, the methods of the present disclosure increase duration of progression-free survival (PFS), duration of response (DOR), duration of complete metabolic response (DoCMR), objective response rate (ORR), overall survival (OS), or any combination thereof, as compared to standard of care and / or prior therapy.

[0251] In some embodiments, the response is characterized according to the Lugano 2014 lymphoma response criteria.

[0252] In some embodiments, the methods of the disclosure reduce the size of a tumor, inhibit the growth of a tumor, eliminate a tumor from a subject, prevent relapse of a hematological cancer, induce remission of a hematological cancer, result in a complete or partial response, or any combination thereof.

[0253] In some embodiments, one or more immune cells in the subject's tumor tissue express LAG-3 (i.e., the patient's tumor tissue is LAG-3 positive) and / or one or more tumor cells in the subject's tumor tissue express PD-L1 (i.e., the patient's tumor tissue is PD-L1 positive). In some embodiments, one or more immune cells in the subject's tumor tissue express LAG-3. In some embodiments, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 7%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the immune cells express LAG-3. In some embodiments, at least about 1% of the immune cells express LAG-3. In some embodiments, more than about 1% of immune cells express LAG-3. In some embodiments, at least about 5% of immune cells express LAG-3. In some embodiments, the immune cells are tumor infiltrating lymphocytes. In some embodiments, the tumor infiltrating lymphocytes are CD8 +In some embodiments, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 7%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in the tumor tissue of the subject express LAG-3 (i.e., immune cells expressing LAG-3 as a percentage of total nucleated cells). In some embodiments, at least about 1% of nucleated cells express LAG-3. In some embodiments, more than about 1% of nucleated cells express LAG-3. In some embodiments, at least about 5% of nucleated cells express LAG-3. In some embodiments, one or more tumor cells in the tumor tissue of the subject express PD-L1. In some embodiments, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 7%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the tumor cells express PD-L1. In some embodiments, at least about 1% of the tumor cells express PD-L1. In some embodiments, more than about 1% of the tumor cells express PD-L1. In some embodiments, at least about 5% of the tumor cells express PD-L1.In some embodiments, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 7%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of nucleated cells in a tumor tissue of a subject express PD-L1 (i.e., tumor cells that express PD-L1 as a percentage of total nucleated cells). In some embodiments, at least about 1% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, at least about 1% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, more than about 1% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, at least about 5% of nucleated cells in a tumor tissue of a subject express PD-L1. In some embodiments, any value of "at least about X%" is "≧X%."

[0254] In some embodiments, one or more immune cells in the patient's tumor tissue do not express LAG-3 (i.e., the patient's tumor tissue is LAG-3 negative). In some embodiments, the tumor tissue is LAG-3 negative if less than about 1% of immune cells express LAG-3. In some embodiments, the tumor tissue is LAG-3 negative if less than about 1% of nucleated cells express LAG-3.

[0255] In some embodiments, one or more immune cells in the patient's tumor tissue do not express PD-1 (i.e., the patient's tumor tissue is PD-1 negative). In some embodiments, the tumor tissue is PD-1 negative if less than about 1% of the immune cells express PD-1. In some embodiments, the tumor tissue is PD-1 negative if less than about 1% of the nucleated cells express PD-1.

[0256] In some embodiments, one or more tumor cells in a patient's tumor tissue do not express PD-L1 (i.e., the patient's tumor tissue is PD-L1 negative). In some embodiments, a tumor tissue is PD-L1 negative if less than about 1% of tumor cells express PD-L1. In some embodiments, a tumor tissue is PD-L1 negative if less than about 1% of nucleated cells express PD-L1.

[0257] In some embodiments, the expression of LAG-3, PD-1, and / or PD-L1 in tumor tissue of a subject is determined from a test tissue sample. In some embodiments, the test tissue sample includes, but is not limited to, any clinically significant tissue sample, such as tumor biopsy, core biopsy, incision biopsy, resection biopsy, surgical specimen, fine needle aspirate, or a sample of bodily fluid, such as blood, plasma, serum, lymph, ascites, cyst fluid, or urine. In some embodiments, the test tissue sample is from a primary tumor. In some embodiments, the test tissue sample is from a metastasis. In some embodiments, the test tissue sample is from multiple time points, such as before, during, and / or after treatment. In some embodiments, the test tissue sample is from different locations in a subject, such as a primary tumor and a metastasis.

[0258] In some embodiments, the test tissue sample is a paraffin-embedded fixed tissue sample. In some embodiments, the test tissue sample is a formalin-fixed paraffin-embedded (FFPE) tissue sample. In some embodiments, the test tissue sample is a fresh tissue (e.g., tumor) sample. In some embodiments, the test tissue sample is a frozen tissue sample. In some embodiments, the test tissue sample is a fresh frozen (FF) tissue (e.g., tumor) sample. In some embodiments, the test tissue sample is cells isolated from a fluid. In some embodiments, the test tissue sample comprises circulating tumor cells (CTCs). In some embodiments, the test tissue sample comprises tumor infiltrating lymphocytes (TILs). In some embodiments, the test tissue sample comprises tumor cells and tumor infiltrating lymphocytes (TILs). In some embodiments, the test tissue sample comprises circulating lymphocytes. In some embodiments, the test tissue sample is an archival tissue sample. In some embodiments, the test tissue sample is an archival tissue sample with a known diagnosis, treatment, and / or outcome history. In some embodiments, the sample is a tissue block. In some embodiments, the test tissue sample is dispersed cells. In some embodiments, the sample size ranges from about 1 cell to about 1 x 10 6 In some embodiments, the sample size ranges from about 1 cell to about 1 x 10 cells or more. 5 In some embodiments, the sample size is about 1 cell to about 10,000 cells. In some embodiments, the sample size is about 1 cell to about 1,000 cells. In some embodiments, the sample size is about 1 cell to about 100 cells. In some embodiments, the sample size is about 1 cell to about 10 cells. In some embodiments, the sample size is a single cell.

[0259] In some embodiments, expression of LAG-3, PD-1, and / or PD-L1 is assessed by performing an assay to detect the presence of LAG-3, PD-1, and / or PD-L1 RNA, respectively. In some embodiments, the presence of LAG-3, PD-1, and / or PD-L1 RNA is detected by RT-PCR, in situ hybridization, or RNase protection.

[0260] In some embodiments, expression of LAG-3, PD-1, and / or PD-L1 is assessed by performing an assay to detect the presence of LAG-3, PD-1, and / or PD-L1 polypeptides, respectively. In some embodiments, the presence of LAG-3, PD-1, and / or PD-L1 polypeptides is detected by immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), in vivo imaging, or flow cytometry.

[0261] II.A. LAG-3 Antagonists LAG-3 antagonists for use in the disclosed methods include, but are not limited to, LAG-3 binding agents and soluble LAG-3 polypeptides. LAG-3 binding agents include antibodies that specifically bind to LAG-3 (i.e., "anti-LAG-3 antibodies"). The term "LAG-3 antagonist" as used herein is interchangeable with the term "LAG-3 inhibitor".

[0262] In some embodiments, the LAG-3 antagonist is an anti-LAG-3 antibody.

[0263] Antibodies that bind to LAG-3 are disclosed, for example, in International Publication No. WO / 2015 / 042246 and U.S. Patent Application Publication Nos. 2014 / 0093511 and 2011 / 0150892, each of which is incorporated by reference in its entirety.

[0264] An exemplary LAG-3 antibody useful in the present disclosure is 25F7 (described in US Patent Application Publication No. 2011 / 0150892). An additional exemplary LAG-3 antibody useful in the present disclosure is BMS-986016 (relatolimab). In some embodiments, an anti-LAG-3 antibody useful in the present disclosure cross-competes with 25F7 or BMS-986016. In some embodiments, an anti-LAG-3 antibody useful in the present disclosure binds to the same epitope as 25F7 or BMS-986016. In some embodiments, an anti-LAG-3 antibody comprises the six CDRs of 25F7 or BMS-986016.

[0265] Other art-recognized anti-LAG-3 antibodies that may be used in the methods of the present disclosure include IMP731 (H5L7BW), described in US2011 / 007023, MK-4280 (28G-10, favezelimab), described in WO2016028672 and U.S. Patent Application Publication No. 2020 / 0055938, Burova E, et al., J. Immunother. Cancer (2016); 4(Supp. 1): P195 and REGN3767 (fianlimab), described in U.S. Pat. No. 10,358,495; humanized BAP050, described in WO2017 / 019894; GSK2831781; IMP-701 (LAG525; yelamirimab), described in U.S. Pat. No. 10,711,060 and U.S. Patent Application Publication No. 2020 / 0172617; aLAG3(0414); aL These include AG3(0416), Sym022, TSR-033, TSR-075, XmAb841 (formerly known as XmAb22841), MGD013 (tevotelimab), BI754111, FS118, P13B02-30, AVA-017, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, and ABL501.These and other anti-LAG-3 antibodies useful in the claimed invention are described, for example, in US 10,188,730, WO2016 / 028672, WO2017 / 106129, WO2017 / 062888, WO2009 / 044273, WO2018 / 069500, WO2016 / 126858 , WO2014 / 179664, WO2016 / 200782, WO2015 / 200119, WO2017 / 019846, WO2017 / 198 741, WO2017 / 220555, WO2017 / 220569, WO2018 / 071500, WO2017 / 015560, WO2017 / 0 25498, WO2017 / 087589, WO2017 / 087901, WO2018 / 083087, WO2017 / 149143, WO201 7 / 219995, US2017 / 0260271, WO2017 / 086367, WO2017 / 086419, WO2018 / 034227, WO No. 2018 / 185046, WO2018 / 185043, WO2018 / 217940, WO19 / 011306, WO2018 / 208868, WO2014 / 140180, WO2018 / 201096, WO2018 / 204374, and WO2019 / 018730, the contents of each of which are incorporated herein by reference in their entirety.

[0266] Anti-LAG-3 antibodies that can be used in the methods of the present disclosure also include isolated antibodies that specifically bind to human LAG-3 and cross-compete for binding to human LAG-3 with any of the anti-LAG-3 antibodies disclosed herein (e.g., leratolimab). In some embodiments, the anti-LAG-3 antibody binds to the same epitope as any of the anti-LAG-3 antibodies described herein (e.g., leratolimab).

[0267] In some embodiments, the antibody that cross-competes with any of the anti-LAG-3 antibodies disclosed herein (e.g., relatolimab) for binding to human LAG-3 or binds to the same epitope region as the antibody is a monoclonal antibody. For administration to human subjects, these cross-competing antibodies are chimeric, engineered, or humanized or human antibodies. Such chimeric, engineered, humanized, or human monoclonal antibodies can be prepared and isolated by methods well known in the art.

[0268] The ability of an antibody to cross-compete for binding to an antigen indicates that the antibody binds to the same epitope region of the antigen, and sterically prevents the binding of other cross-competing antibodies to that particular epitope region.These cross-competing antibodies are expected to have functional properties very similar to those of reference antibodies such as relatolimab, because they bind to the same epitope region.Cross-competing antibodies can be easily identified based on their ability to cross-compete in standard binding assays such as Biacore analysis, ELISA assay, or flow cytometry (see, for example, WO2013 / 173223).

[0269] Anti-LAG-3 antibodies that can be used in the methods of the present disclosure include antigen-binding portions of any of the full-length antibodies described above. It is well established that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.

[0270] In some embodiments, the anti-LAG-3 antibody is a full-length antibody.

[0271] In some embodiments, the anti-LAG-3 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a dual affinity retargeting antibody (DART), a DVD-Ig, or a bispecific antibody.

[0272] In some embodiments, the anti-LAG-3 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

[0273] In some embodiments, the anti-LAG-3 antibody is selected from the group consisting of BMS-986016 (leratolimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, yelamirimab), aLAG3(0414), aLAG3(0416), Sym022, TS R-033, TSR-075, XmAb841 (XmAb22841), MGD013 (tevotelimab), BI754111, FS118, P13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof.

[0274] In some embodiments, the anti-LAG-3 antibody is leratolimab.

[0275] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4.

[0276] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:5; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:6; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:7; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:8; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:9; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:10.

[0277] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 3 and 4, respectively.

[0278] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively.

[0279] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs:21 and 2, respectively.

[0280] In some embodiments, the anti-LAG-3 antibody is MGD013 (tebotelimab), a bispecific PD-1 x LAG-3 DART. In some embodiments, tebotelimab is administered intravenously at a dose of about 300 mg or about 600 mg once every 2 or 3 weeks. In some embodiments, tebotelimab is administered intravenously at a dose of about 300 mg once every 2 weeks. In some embodiments, tebotelimab is administered intravenously at a dose of about 600 mg once every 3 weeks.

[0281] In some embodiments, the anti-LAG-3 antibody is REGN3767 (fianlimab). In some embodiments, fianlimab is administered intravenously at a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, or about 20 mg / kg once every 3 weeks. In some embodiments, fianlimab is administered intravenously at a dose of about 1600 mg once every 3 weeks. In some embodiments, the method of the present disclosure includes an anti-LAG-3 antibody comprising the CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:25, and the CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:26.

[0282] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:27; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:28; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:29; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:30; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:31; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:32.

[0283] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:25 and 26, respectively.

[0284] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs:23 and 24, respectively.

[0285] In some embodiments, the anti-LAG-3 antibody is LAG525 (Yelamirimab). In some embodiments, Yelamirimab is administered intravenously at a dose of about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, or about 1300 mg about once every 2, 3, or 4 weeks.

[0286] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:47, and CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:49.

[0287] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:48, and CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:50.

[0288] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:51; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:52; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:53; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:54; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:55; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:56.

[0289] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 47 and 49, respectively.

[0290] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 48 and 50, respectively.

[0291] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 43 and 45, respectively.

[0292] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 44 and 46, respectively.

[0293] In some embodiments, the anti-LAG-3 antibody is MK4280 (fabezelimab). In some embodiments, favezelimab is administered intravenously at a dose of about 7 mg, about 21 mg, about 70 mg, about 210 mg, about 700 mg, or about 800 mg once about every 3 weeks or once about every 6 weeks. In some embodiments, favezelimab is administered intravenously at a dose of about 200 mg once about every 3 weeks. In some embodiments, favezelimab is administered intravenously at a dose of about 800 mg once about every 6 weeks. In some embodiments, favezelimab is administered intravenously at a dose of about 800 mg on day 1, then once about every 3 weeks. In some embodiments, favezelimab is administered for up to 35 cycles. In some embodiments, favezelimab is administered intravenously at a dose of about 800 mg for about 30 minutes on day 1 of a 3 week cycle for up to 35 cycles.

[0294] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:69, and CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:70.

[0295] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 71; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 72; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 73; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 74; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 75; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 76.

[0296] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 69 and 70, respectively.

[0297] In some embodiments, the methods of the disclosure include an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 67 and 68, respectively.

[0298] In some embodiments, the LAG-3 antagonist is a soluble LAG-3 polypeptide. In some embodiments, the soluble LAG-3 polypeptide is a fusion polypeptide, such as a fusion protein comprising the extracellular portion of LAG-3. In some embodiments, the soluble LAG-3 polypeptide is a LAG-3-Fc fusion polypeptide capable of binding to MHC class II. In some embodiments, the soluble LAG-3 polypeptide comprises a ligand-binding fragment of the LAG-3 extracellular domain. In some embodiments, the ligand-binding fragment of the LAG-3 extracellular domain comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100% sequence identity with SEQ ID NO:22. In some embodiments, the soluble LAG-3 polypeptide further comprises a half-life extending moiety. In some embodiments, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin binding polypeptide, an immunoglobulin G (IgG), an albumin binding polypeptide (ABP), a PAS-modified portion, a HES-modified portion, an XTEN, a PEGylated portion, an Fc region, or any combination thereof. In some embodiments, the soluble LAG-3 polypeptide is IMP321 (eftiragimodo alpha). See, for example, Brignone C, et al., J. Immunol. (2007); 179:4202-4211 and WO2009 / 044273. In some embodiments, eftiragimodo alpha is administered at a dose of about 30 mg. In some embodiments, eftiragimodo alpha is administered subcutaneously at a dose of about 30 mg once about every two weeks.

[0299] In some embodiments, anti-LAG-3 antibodies are used to determine LAG-3 expression. In some embodiments, anti-LAG-3 antibodies are selected for their ability to bind to LAG-3 in formalin-fixed paraffin-embedded (FFPE) tissue specimens. In some embodiments, anti-LAG-3 antibodies are capable of binding to LAG-3 in frozen tissue. In some embodiments, anti-LAG-3 antibodies are capable of distinguishing between membrane-bound, cytoplasmic, and / or soluble forms of LAG-3.

[0300] In some embodiments, an anti-LAG-3 antibody useful for assaying, detecting, and / or quantifying LAG-3 expression according to the methods disclosed herein is the 17B4 mouse IgG1 anti-human LAG-3 monoclonal antibody. See, e.g., Matsuzaki, J et al., PNAS (2010); 107:7875.

[0301] In some embodiments, the LAG-3 antagonist is formulated for intravenous administration.

[0302] In some embodiments, the anti-LAG-3 antibody is administered intravenously over a period of about 30 minutes.

[0303] In some embodiments, the LAG-3 antagonist is administered in a fixed dose.

[0304] In some embodiments, the LAG-3 antagonist is at least about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, The compound is administered in a dose of about 20 mg to about 100 mg, about 100 mg to about 2000 mg, about 100 mg to about 1800 mg, about 100 mg to about 1600 mg, about 100 mg to about 1400 mg, about 100 mg to about 1200 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about 400 mg, about 400 mg to about 2000 mg, about 400 mg to about 1800 mg, about 400 mg to about 1600 mg, about 400 mg to about 1400 mg, about 400 mg to about 1200 mg, or about 400 mg to about 1000 mg.

[0305] In some embodiments, the LAG-3 antagonist is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75mg, about 10mg, about 20mg, about 30mg, about 40mg, about 50mg, about 60mg, about 70mg, about 80mg, about 90mg, about 100mg, about 110mg, about 120mg, about 130mg, about 140mg, about 150mg, about 160mg, about 170mg, about 18 0mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 35 0mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 52 0mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 69 0mg, about 700mg, about 710mg, about 720mg, about 730mg, about 740mg, about 750mg, about 760mg, about 770mg, about 780mg, about 790mg, about 800mg, about 810mg, about 820mg, about 830mg, about 840mg, about 850mg, about 8 60mg, about 870mg, about 880mg, about 890mg, about 900mg, about 910mg, about 920mg, about 930mg, about 940mg, about 950mg, about 960mg, about 970mg, about 980mg, about 990mg, about 1000mg, about 1040mg, about 1080mg , about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg.

[0306] In some embodiments, the LAG-3 antagonist is administered at a weight-based dose.

[0307] In some embodiments, the LAG-3 antagonist is administered in a dose range of about 0.003 mg / kg to about 25 mg / kg, about 0.003 mg / kg to about 20 mg / kg, about 0.003 mg / kg to about 15 mg / kg, about 0.003 mg / kg to about 10 mg / kg, about 0.003 mg / kg to about 5 mg / kg, about 0.003 mg / kg to about 1 mg / kg, about 0.003 mg / kg to about 0.9 mg / kg, about 0.003 mg / kg to about 10 ... about 0.8 mg / kg, about 0.003 mg / kg to about 0.7 mg / kg, about 0.003 mg / kg to about 0.6 mg / kg, about 0.003 mg / kg to about 0.5 mg / kg, about 0.003 mg / kg to about 0.4 mg / kg, about 0.003 mg / kg to about 0.3 mg / kg, about 0.003 mg / kg to about 0.2 mg / kg, about 0.003 mg / kg to about 0.1 mg / kg, about 0.1 mg / kg to about 25 mg / kg, about 0.1 mg / kg to about 20 mg / kg, about 0.1 mg / kg to about 15 mg / kg, about 0.1 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 5 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 1 mg / kg to about 25 mg / kg, about 1 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, about 1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 5 mg / kg, about 5 mg / kg g to about 25 mg / kg, about 5 mg / kg to about 20 mg / kg, about 5 mg / kg to about 15 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 25 mg / kg, about 10 mg / kg to about 20 mg / kg, about 10 mg / kg to about 15 mg / kg, about 15 mg / kg to about 25 mg / kg, about 15 mg / kg to about 20 mg / kg, or about 20 mg / kg to about 25 mg / kg.

[0308] In some embodiments, the LAG-3 antagonist is about 0.003 mg / kg, about 0.004 mg / kg, about 0.005 mg / kg, about 0.006 mg / kg, about 0.007 mg / kg, about 0.008 mg / kg, about 0.009 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, The compound is administered at a dose of about 0.9 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 7.0 mg / kg, about 8.0 mg / kg, about 9.0 mg / kg, about 10.0 mg / kg, about 11.0 mg / kg, about 12.0 mg / kg, about 13.0 mg / kg, about 14.0 mg / kg, about 15.0 mg / kg, about 16.0 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, or about 25.0 mg / kg.

[0309] In some embodiments, the dose is administered about once every week, about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, about once every 10 weeks, about once every 11 weeks, or about once every 12 weeks.

[0310] In some embodiments, the LAG-3 antagonists described herein are administered as monotherapy, ie, the LAG-3 antagonists are not administered in combination with one or more additional therapeutic agents.

[0311] In some embodiments, the LAG-3 antagonists described herein are administered as a combination therapy, i.e., the LAG-3 antagonist is administered in combination with one or more additional therapeutic agents and / or anti-cancer therapies.

[0312] II.B Additional Therapeutic Agents and Therapies In some embodiments, the method of the present disclosure further comprises administering to the subject an additional therapeutic agent and / or anti-cancer therapy.The additional therapeutic agent and / or anti-cancer therapy can include any known therapeutic agent or anti-cancer therapy, including the standard therapy in the art for treating subjects suffering from hematological cancer, such as those described by the NCCN Guidelines®.

[0313] In some embodiments, the additional anti-cancer therapy comprises surgery, radiation therapy, chemotherapy, immunotherapy, or any combination thereof. In some embodiments, the additional anti-cancer therapy comprises chemotherapy, including any chemotherapeutic agent disclosed herein.

[0314] In some embodiments, the additional therapeutic agent comprises an anti-cancer agent, hi some embodiments, the anti-cancer agent comprises a tyrosine kinase inhibitor, an anti-angiogenic agent, a checkpoint inhibitor, a checkpoint stimulator, a chemotherapeutic agent, an immunotherapeutic agent, a platinum agent, an alkylating agent, a taxane, a nucleoside analog, an antimetabolite, a topoisomerase inhibitor, an anthracycline, a vinca alkaloid, or any combination thereof.

[0315] In some embodiments, the tyrosine kinase inhibitor is sorafenib (e.g., sorafenib tosylate, a.k.a., NEXAVAR®), lenvatinib (e.g., lenvatinib mesylate, a.k.a., LENVIMA®), regorafenib (e.g., STIVARGA®), cabozantinib (e.g., cabozantinib S-malate, a.k.a., CABOMETYX®), sunitinib (e.g., sunitinib malate, a.k.a., SUTENT®), brivanib, linifanib, pemigatinib (a.k.a., PEMAZ), YRE™)], everolimus [aka AFINITOR® or ZORTRESS®], gefitinib [IRESSA®, a small molecule TKI for EGFR], imatinib (e.g., imatinib mesylate), lapatinib [e.g., lapatinib ditosylate, aka TYKERB®], nilotinib [e.g., nilotinib hydrochloride, aka TASIGNA®], pazopanib [e.g., pazopanib hydrochloride, aka VOTRIENT®], temsirolimus [aka TORISEL®], eltrombopag [e.g., eltrombopag Lotinib [e.g., erlotinib hydrochloride, also known as TARCEVA®, a small molecule TKI for EGFR], afatinib [GILOTRIF®, a small molecule TKI for EGFR], dacomitinib [VIZIMPRO®, a small molecule TKI for EGFR], osimeritinib [TAGRISSO®, a small molecule TKI for EGFR], alectinib [ALECENSA®, a small molecule TKI for ALK], ceritinib [ZYKADIA®, a small molecule TKI for ALK and ROS-1], brigatinib [ ALUNBRIG®, a small molecule TKI for ALK], crizotinib [XALKORI®, a small molecule TKI for ALK and ROS-1], lorlatinib [LORBRENA®, a small molecule TKI for ALK and ROS-1], entrectinib [ROZLYTREK®, a small molecule TKI for ROS-1 and NTRK], dabrafenib [TAFINLAR®, a small molecule TKI for BRAF] trametinib [MEKINIST®, a small molecule TKI for BRAF], vemurafenib [ZELBORAF®,BRAF small molecule TKI], larotrectinib (ROZLYTREK®, an NTRK small molecule TKI), or any combination thereof.

[0316] In some embodiments, the antiangiogenic agent comprises an inhibitor of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), angiopoietin (Ang), tyrosine kinase with Ig-like and EGF-like domains (Tie) receptor, hepatocyte growth factor (HGF), tyrosine protein kinase Met (c-MET), C-type lectin family 14 member A (CLEC14A), multimerin 2 (MMRN2), shock protein 70-1A (HSP70-1A), epidermal growth factor (EGF), EGFR, or any combination thereof. In some embodiments, the antiangiogenic agent comprises bevacizumab (aka AVASTIN®), ramucirumab (aka CYRAMZA®), aflibercept (aka EYLEA® or ZALTRAP®), tanibirumab, olaratumab (aka LARTRUVO™), nesvacumab, AMG780, MEDI3617, vanucizumab, rilotumumab, ficlatuzumab, TAK-701, onartuzumab, emibetuzumab, or any combination thereof.

[0317] In some embodiments, checkpoint stimulators include agonists of B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, GITR, inducible T cell costimulator (ICOS), ICOS-L, OX40, OX40L, CD70, CD27, CD40, death receptor 3 (DR3), CD28H, or any combination thereof.

[0318] In some embodiments, the chemotherapeutic agent comprises an alkylating agent, antimetabolite, an antitumor antibiotic, an antimitotic, a hormone or hormone modulating agent, a protein tyrosine kinase inhibitor, an epidermal growth factor inhibitor, a proteasome inhibitor, another antitumor agent, or any combination thereof.

[0319] In some embodiments, the immunotherapeutic agent comprises an antibody that specifically binds to EGFR [e.g., cetuximab (ERBITUX®)], ALK, ROS-1, NTRK, BRAF, ICOS, CD137 (4-1BB), CD134 (OX40), NKG2A, CD27, CD96, GITR, herpes virus entry mediator (HVEM), PD-1, PD-L1, CTLA-4, BTLA, TIM-3, A2aR, killer cell lectin-like receptor G1 (KLRG-1), natural killer cell receptor 2B4 (CD244), CD160, TIGIT, VISTA, KIR, TGFβ, IL-10, IL-8, B7-H4, Fas ligand, CSF1R, CXCR4, mesothelin, CEACAM-1, CD52, HER2, MICA, MICB, or any combination thereof.

[0320] In some embodiments, the platinum agent comprises cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin (eg, triplatin tetranitrate), lipoplatin, phenanthriplatin, or any combination thereof.

[0321] In some embodiments, the alkylating agent comprises altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, procarbazine, streptozocin, temozolomide, thiotepa, or any combination thereof.

[0322] In some embodiments, the taxane comprises paclitaxel, albumin-bound paclitaxel (ie, nab-paclitaxel), docetaxel, cabazitaxel, or any combination thereof.

[0323] In some embodiments, the nucleoside analog comprises cytarabine, gemcitabine, lamivudine, entecavir, telbivudine, or any combination thereof.

[0324] In some embodiments, the antimetabolite comprises capecitabine, cladribine, clofarabine, cytarabine, floxuridine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, pemetrexed, pentostatin, pralatrexate, thioguanine, or any combination thereof.

[0325] In some embodiments, the topoisomerase inhibitor comprises etoposide, mitoxantrone, doxorubicin, irinotecan, topotecan, camptothecin, or any combination thereof.

[0326] In some embodiments, the anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, or any combination thereof.

[0327] In some embodiments, the vinca alkaloid is vinblastine, vincristine, vinorelbine, vindesine, vincaminol, vineridine, vinbrunin, or any combination thereof.

[0328] II.B.1. Checkpoint inhibitors In some embodiments, the anti-cancer agent administered as an additional therapeutic agent in the methods of the present disclosure is a checkpoint inhibitor.

[0329] In some embodiments, the checkpoint inhibitor is a programmed death 1 (PD-1) pathway inhibitor, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, a T-cell immunoglobulin and ITIM domain (TIGIT) inhibitor, a T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) inhibitor, a TIM-1 inhibitor, a TIM-4 inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, a B- and T-cell lymphocyte attenuator (BTLA) inhibitor, a T-cell V domain Ig suppressor of cellular activation (VISTA) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors [e.g., indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors, epacadostat (INCB24360), navoximide (GDC-0919), or linrodostat (BMS-986205), including linrodostat salts, e.g., linrodostat mesylate], nicotinamide adenine dinucleotide phosphate and / or any combination thereof.

[0330] In some embodiments, the checkpoint inhibitor is formulated for intravenous administration.

[0331] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are formulated separately. In some embodiments, when the checkpoint inhibitor comprises multiple checkpoint inhibitors, each checkpoint inhibitor is formulated separately. In some embodiments, the checkpoint inhibitor is administered before the LAG-3 antagonist. In some embodiments, the LAG-3 antagonist is administered before the checkpoint inhibitor.

[0332] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are formulated together. In some embodiments, when the checkpoint inhibitor comprises multiple checkpoint inhibitors, two or more checkpoint inhibitors are formulated together.

[0333] In some embodiments, the LAG-3 antagonist and the checkpoint inhibitor are administered simultaneously.

[0334] In some embodiments, the checkpoint inhibitor is administered in a fixed dose.

[0335] In some embodiments, the checkpoint inhibitor is at least about 0.25 mg to about 2000 mg, about 0.25 mg to about 1600 mg, about 0.25 mg to about 1200 mg, about 0.25 mg to about 800 mg, about 0.25 mg to about 400 mg, about 0.25 mg to about 100 mg, about 0.25 mg to about 50 mg, about 0.25 mg to about 40 mg, about 0.25 mg to about 30 mg, about 0.25 mg to about 20 mg, about 20 mg to about 2000 mg, about 20 mg to about 1600 mg, about 20 mg to about 1200 mg, about 20 mg to about 800 mg, about 20 mg to about 400 mg, about The compound is administered in a dose of from about 20 mg to about 100 mg, from about 100 mg to about 2000 mg, from about 100 mg to about 1800 mg, from about 100 mg to about 1600 mg, from about 100 mg to about 1400 mg, from about 100 mg to about 1200 mg, from about 100 mg to about 1000 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 100 mg to about 400 mg, from about 400 mg to about 2000 mg, from about 400 mg to about 1800 mg, from about 400 mg to about 1600 mg, from about 400 mg to about 1400 mg, from about 400 mg to about 1200 mg, or from about 400 mg to about 1000 mg.

[0336] In some embodiments, the checkpoint inhibitor is about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3 mg, about 3.25 mg, about 3.5 mg, about 3.75 mg, about 4 mg, about 4.25 mg, about 4.5 mg, about 4.75 mg, about 5 mg, about 5.25 mg, about 5.5 mg, about 5.75 mg, about 6 mg, about 6.25 mg, about 6.5 mg, about 6.75 mg, about 7 mg, about 7.25 mg, about 7.5 mg, about 7.75 mg, about 8 mg, about 8.25 mg, about 8.5 mg, about 8.75 mg, about 9 mg, about 9.25 mg, about 9.5 mg, about 9.75mg, about 10mg, about 20mg, about 30mg, about 40mg, about 50mg, about 60mg, about 70mg, about 80mg, about 90mg, about 100mg, about 110mg, about 120mg, about 130mg, about 140mg, about 150mg, about 160mg, about 170mg, about 18 0mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 35 0mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 52 0mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 69 0mg, about 700mg, about 710mg, about 720mg, about 730mg, about 740mg, about 750mg, about 760mg, about 770mg, about 780mg, about 790mg, about 800mg, about 810mg, about 820mg, about 830mg, about 840mg, about 850mg, about 8 60mg, about 870mg, about 880mg, about 890mg, about 900mg, about 910mg, about 920mg, about 930mg, about 940mg, about 950mg, about 960mg, about 970mg, about 980mg, about 990mg, about 1000mg, about 1040mg, about 1080mg , about 1100 mg, about 1140 mg, about 1180 mg, about 1200 mg, about 1240 mg, about 1280 mg, about 1300 mg, about 1340 mg, about 1380 mg, about 1400 mg, about 1440 mg, about 1480 mg, about 1500 mg, about 1540 mg, about 1580 mg, about 1600 mg, about 1640 mg, about 1680 mg, about 1700 mg, about 1740 mg, about 1780 mg, about 1800 mg, about 1840 mg, about 1880 mg, about 1900 mg, about 1940 mg, about 1980 mg, or about 2000 mg.

[0337] In some embodiments, the checkpoint inhibitor is administered as a weight-based dose.

[0338] In some embodiments, the checkpoint inhibitor is administered in a dose range of about 0.003 mg / kg to about 25 mg / kg, about 0.003 mg / kg to about 20 mg / kg, about 0.003 mg / kg to about 15 mg / kg, about 0.003 mg / kg to about 10 mg / kg, about 0.003 mg / kg to about 5 mg / kg, about 0.003 mg / kg to about 1 mg / kg, about 0.003 mg / kg to about 0.9 mg / kg, about 0.003 mg / kg to about 0.8mg / kg, about 0.003mg / kg to about 0.7mg / kg, about 0.003mg / kg to about 0.6mg / kg, about 0.003mg / kg to about 0.5mg / kg, about 0.003mg / kg to about 0.4mg / kg, about 0.003mg / kg to about 0.3mg / kg, about 0.003mg / kg to about 0.2mg / kg, about 0.003mg / kg to about 0.1mg / kg, about 0.1mg / kg to about 25mg / kg, about 0 .1mg / kg to about 20mg / kg, about 0.1mg / kg to about 15mg / kg, about 0.1mg / kg to about 10mg / kg, about 0.1mg / kg to about 5mg / kg, about 0.1mg / kg to about 1mg / kg, about 1mg / kg to about 25mg / kg, about 1mg / kg to about 20mg / kg, about 1mg / kg to about 15mg / kg, about 1mg / kg to about 10mg / kg, about 1mg / kg to about 5mg / kg, about 5mg / kg to about 25 mg / kg, about 5 mg / kg to about 20 mg / kg, about 5 mg / kg to about 15 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 25 mg / kg, about 10 mg / kg to about 20 mg / kg, about 10 mg / kg to about 15 mg / kg, about 15 mg / kg to about 25 mg / kg, about 15 mg / kg to about 20 mg / kg, or about 20 mg / kg to about 25 mg / kg.

[0339] In some embodiments, the checkpoint inhibitor is about 0.003 mg / kg, about 0.004 mg / kg, about 0.005 mg / kg, about 0.006 mg / kg, about 0.007 mg / kg, about 0.008 mg / kg, about 0.009 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, The compound is administered at a dose of about 0.9 mg / kg, about 1.0 mg / kg, about 2.0 mg / kg, about 3.0 mg / kg, about 4.0 mg / kg, about 5.0 mg / kg, about 6.0 mg / kg, about 7.0 mg / kg, about 8.0 mg / kg, about 9.0 mg / kg, about 10.0 mg / kg, about 11.0 mg / kg, about 12.0 mg / kg, about 13.0 mg / kg, about 14.0 mg / kg, about 15.0 mg / kg, about 16.0 mg / kg, about 17.0 mg / kg, about 18.0 mg / kg, about 19.0 mg / kg, about 20.0 mg / kg, about 21.0 mg / kg, about 22.0 mg / kg, about 23.0 mg / kg, about 24.0 mg / kg, or about 25.0 mg / kg.

[0340] In some embodiments, doses of the checkpoint inhibitor are administered every 1 week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 11 weeks, or every 12 weeks.

[0341] In some embodiments, each dose of the LAG-3 antagonist and / or checkpoint inhibitor is administered in a fixed amount.

[0342] In some embodiments, each dose of LAG-3 antagonist and / or checkpoint inhibitor is administered in variable amounts.For example, in some embodiments, the maintenance (or subsequent) dose of LAG-3 antagonist and / or checkpoint inhibitor can be higher than or the same as the loading dose that is first administered.In some embodiments, the maintenance dose of LAG-3 antagonist and / or checkpoint inhibitor can be lower than or the same as the loading dose.

[0343] II.B.1.a. PD-1 pathway inhibitors In some embodiments, a checkpoint inhibitor for use in the methods of the disclosure comprises a PD-1 pathway inhibitor.

[0344] In some embodiments, the PD-1 pathway inhibitor is a PD-1 inhibitor and / or a PD-L1 inhibitor.

[0345] In some embodiments, the PD-1 inhibitor and / or the PD-L1 inhibitor is a small molecule.

[0346] In some embodiments, the PD-1 inhibitor and / or the PD-L1 inhibitor is a millamolecule.

[0347] In some embodiments, the PD-1 inhibitor and / or the PD-L1 inhibitor is a macrocyclic peptide.

[0348] In certain embodiments, the PD-1 inhibitor and / or PD-L1 inhibitor is BMS-986189.

[0349] In some embodiments, the PD-1 inhibitor is an inhibitor disclosed in International Publication No. WO2014 / 151634, which is incorporated by reference in its entirety.

[0350] In some embodiments, the PD-1 inhibitor is INCMGA00012 (Insight Pharmaceuticals).

[0351] In some embodiments, the PD-1 inhibitor comprises a combination of an anti-PD-1 antibody disclosed herein and a PD-1 small molecule inhibitor.

[0352] In some embodiments, the PD-L1 inhibitor has formula (I): [ka] wherein R 1 ~R 13 is the amino acid side chain, and R a ~R n is hydrogen, methyl, or forms a ring together with the adjacent R group; R 14 is -C(O)NHR 15 (In the formula, R 15 is hydrogen, or a glycine residue optionally substituted with additional glycine residues and / or a tail that may improve pharmacokinetic properties. In some embodiments, the PD-L1 inhibitor comprises a compound disclosed in International Publication No. WO2014 / 151634, which is incorporated herein by reference in its entirety. In some embodiments, the PD-L1 inhibitor comprises a compound disclosed in International Publication No. WO2016 / 039749, WO2016 / 149351, WO2016 / 077518, WO2016 / 100285, WO2016 / 100608, WO2016 / 126646, WO2016 / 057624, WO2017 / 151830, WO2017 / 176608, WO2018 / 085750, WO2018 / 237153, or WO2019 / 070643, each of which is incorporated by reference herein in its entirety.

[0353] In some embodiments, the PD-L1 inhibitor comprises a small molecule PD-L1 inhibitor disclosed in International Publication No. WO2015 / 034820, WO2015 / 160641, WO2018 / 044963, WO2017 / 066227, WO2018 / 009505, WO2018 / 183171, WO2018 / 118848, WO2019 / 147662, or WO2019 / 169123, each of which is incorporated by reference in its entirety.

[0354] In some embodiments, the PD-1 pathway inhibitor is a soluble PD-L2 polypeptide. In some embodiments, the soluble PD-L2 polypeptide is a fusion polypeptide. In some embodiments, the soluble PD-L2 polypeptide comprises a ligand-binding fragment of the PD-L2 extracellular domain. In some embodiments, the soluble PD-L2 polypeptide further comprises a half-life extending moiety. In some embodiments, the half-life extending moiety comprises an immunoglobulin constant region or a portion thereof, an immunoglobulin binding polypeptide, an immunoglobulin G (IgG), an albumin binding polypeptide (ABP), a PASylated moiety, a HESylated moiety, an XTEN, a PEGylated moiety, an Fc region, or any combination thereof. In some embodiments, the soluble PD-L2 polypeptide is AMP-224 (see, e.g., US2013 / 0017199).

[0355] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-1 antibody and / or an anti-PD-L1 antibody.

[0356] II.B.1.ai Anti-PD-1 antibody Anti-PD-1 antibodies known in the art can be used in the methods of the present disclosure. Various human monoclonal antibodies that specifically bind to PD-1 with high affinity are disclosed in U.S. Patent No. 8,008,449. The anti-PD-1 human antibodies disclosed in U.S. Patent No. 8,008,449 have been demonstrated to exhibit one or more of the following characteristics: (a) a 1×10 IgG antibody binding affinity as determined by surface plasmon resonance using a Biacore biosensor system; -7 K below M D (b) does not substantially bind to human CD28, CTLA-4, or ICOS; (c) increases T-cell proliferation in a mixed lymphocyte reaction (MLR) assay; (d) increases interferon-γ production in an MLR assay; (e) increases IL-2 secretion in an MLR assay; (f) binds to human PD-1 and cynomolgus PD-1; (g) inhibits binding of PD-L1 and / or PD-L2 to PD-1; (h) stimulates an antigen-specific memory response; (i) stimulates an antibody response; and (j) inhibits tumor cell growth in vivo. Anti-PD-1 antibodies that can be used in the present disclosure include monoclonal antibodies that specifically bind human PD-1 and exhibit at least one, and in some embodiments at least five, of the foregoing characteristics.

[0357] Other anti-PD-1 monoclonal antibodies that may be used in the methods of the disclosure are described in, e.g., U.S. Pat. Nos. 6,808,710, 7,488,802, 8,168,757, and 8,354,509, U.S. Patent Application Publication No. 2016 / 0272708, and PCT Publication Nos. WO2012 / 145493, WO2008 / 156712, and the like. , WO2015 / 112900, WO2012 / 145493, WO2015 / 112800, WO2014 / 206107, WO2015 / 35 606, WO2015 / 085847, WO2014 / 179664, WO2017 / 020291, WO2017 / 020858, WO2016 / 197367, WO2017 / 024515, WO2017 / 025051, WO2017 / 123557, WO2016 / 106159, W O2014 / 194302, WO2017 / 040790, WO2017 / 133540, WO2017 / 132827, WO2017 / 024465 , WO2017 / 025016, WO2017 / 106061, WO2017 / 19846, WO2017 / 024465, WO2017 / 025016, WO2017 / 132825, and WO2017 / 133540, each of which is incorporated by reference in its entirety.

[0358] Anti-PD-1 antibodies that may be used in the methods of the disclosure include nivolumab (aka OPDIVO®, 5C4, BMS-936558, MDX-1106, and ONO-4538), pembrolizumab (Merck; aka KEYTRUDA®, lambrolizumab, and MK3475; see WO 2008 / 156712), PDR001 (Novartis; aka spartalizumab; see WO 2015 / 112900 and U.S. Patent No. 9,683,048), MEDI-0680 (AstraZeneca; aka AMP-514; see WO 2012 / 145493), TSR-042 (Tesaro Biopharmaceutical; aka ANB011 or dostallimab; see WO2014 / 179664), cemiplimab [Regeneron; aka LIBTAYO® or REGN2810; see WO2015 / 112800 and U.S. Patent No. 9,987,500], JS001 [TAIZHOU JUNSHI PHARMA; aka toripalimab; Si-Yang Liu et al., J. Hematol. Oncol. 10:136 (2017)], PF-06801591 (Pfizer; also known as sasanlimab; US2016 / 0159905), BGB-A317 (Beigene; also known as tislelizumab; see WO2015 / 35606 and US2015 / 0079109), BI754091 [Boehringer Ingelheim; see Zettl M et al., Cancer. Res. (2018);78(13 Suppl):Abstract 4558], INCSHR1210 [Jiangsu Hengrui Medicine; also known as SHR-1210 or camrelizumab; WO2015 / 085847; Si-Yang Liu et al., J. Hematol. Oncol. 10:136 (2017)], GLS-010 [Wuxi / Harbin Gloria Pharmaceuticals; also known as WBP3055; Si-Yang Liu et al., J. Hematol. Oncol.10:136 (2017)], AM-0001 (Armo), STI-1110 (Sorrento Therapeutics; see WO2014 / 194302), AGEN2034 (Agenus; see WO2017 / 040790), MGA012 (Macrogenics; see WO2017 / 19846), BCD-100 [Biocad; Kaplon et al., mAbs 10(2):183-203 (2018)], IBI308 (Innovent; also known as sintilimab; see WO2017 / 024465, WO2017 / 025016, WO2017 / 132825, and WO2017 / 133540), and SSI-361 (Lyvgen Biopharma Holdings Limited, US2018 / 0346569).

[0359] Anti-PD-1 antibodies that can be used in the methods of the disclosure also include isolated antibodies that specifically bind to human PD-1 and cross-compete for binding to human PD-1 with any of the anti-PD-1 antibodies disclosed herein (e.g., nivolumab) (see, e.g., U.S. Patent Nos. 8,008,449 and 8,779,105; WO 2013 / 173223). In some embodiments, the anti-PD-1 antibody binds to the same epitope as any of the anti-PD-1 antibodies described herein (e.g., nivolumab).

[0360] In some embodiments, the antibody that cross-competes for binding to human PD-1 or binds to the same epitope region as any of the anti-PD-1 antibodies disclosed herein (e.g., nivolumab) is a monoclonal antibody. For administration to human subjects, these cross-competing antibodies are chimeric, engineered, or humanized or human antibodies. Such chimeric, engineered, humanized, or human monoclonal antibodies can be prepared and isolated by methods well known in the art.

[0361] Anti-PD-1 antibodies that can be used in the methods of the disclosure include antigen-binding portions of any of the full-length antibodies described above.

[0362] The anti-PD-1 antibodies that may be used in the methods of the present disclosure are those that bind to PD-1 with high specificity and affinity, block the binding of PD-L1 and / or PD-L2, and inhibit the immunosuppressive effects of the PD-1 signaling pathway. In any of the compositions or methods disclosed herein, the anti-PD-1 "antibody" includes an antigen-binding portion or fragment that binds to the PD-1 receptor and exhibits functional properties similar to those of the whole antibody in inhibiting ligand binding and upregulating the immune system. In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof cross-competes with nivolumab for binding to human PD-1.

[0363] In some embodiments, the anti-PD-1 antibody is a full-length antibody. In some embodiments, the anti-PD-1 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0364] In some embodiments, the anti-PD-1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0365] In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or comprises an antigen-binding portion thereof.

[0366] In some embodiments, the anti-PD-1 antibody is formulated for intravenous administration.

[0367] In some embodiments, the anti-PD-1 antibody is administered intravenously over a period of about 30 minutes.

[0368] In some embodiments, the anti-PD-1 antibody is nivolumab, a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking downregulation of anti-tumor T cell function (U.S. Patent No. 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(9):846-56).

[0369] In some embodiments, nivolumab is administered at a fixed dose of about 240mg once every about 2 weeks.In some embodiments, nivolumab is administered at a fixed dose of about 240mg once every about 3 weeks.In some embodiments, nivolumab is administered at a fixed dose of about 360mg once every about 3 weeks.In some embodiments, nivolumab is administered at a fixed dose of about 480mg once every about 4 weeks.

[0370] In some embodiments, nivolumab is administered intravenously over about 30 minutes on day 1 of a two-week cycle at a dose of about 240 mg.

[0371] In some embodiments, nivolumab is administered intravenously over about 30 minutes on day 1 of a 4 week cycle at a dose of about 480 mg.

[0372] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14.

[0373] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 15; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 16; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 17; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 18; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 19; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 20.

[0374] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 13 and 14, respectively.

[0375] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs:11 and 12, respectively.

[0376] In some embodiments, the methods of the disclosure include a combination of leratolimab and nivolumab.

[0377] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4, and (b) an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14.

[0378] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively; and (b) an anti-PD-1 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively.

[0379] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 3 and 4, respectively; and (b) an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 13 and 14, respectively.

[0380] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 11 and 12, respectively.

[0381] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs:21 and 2, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs:11 and 12, respectively.

[0382] In some embodiments, the anti-PD-1 antibody is pembrolizumab. Pembrolizumab is a humanized monoclonal IgG4 (S228P) antibody directed against the human cell surface receptor PD-1. Pembrolizumab is described, for example, in U.S. Patent Nos. 8,354,509 and 8,900,587.

[0383] In some embodiments, pembrolizumab is administered at a fixed dose of about 200 mg once about every 2 weeks. In some embodiments, pembrolizumab is administered at a fixed dose of about 200 mg once about every 3 weeks. In some embodiments, pembrolizumab is administered at a fixed dose of about 400 mg once about every 6 weeks. In some embodiments, pembrolizumab is administered at a fixed dose of about 300 mg once about every 4-5 weeks.

[0384] In some embodiments, pembrolizumab is administered intravenously at a dose of about 200 mg on day 1, then about once every 3 weeks. In some embodiments, pembrolizumab is administered for up to 35 cycles. In some embodiments, pembrolizumab is administered intravenously at a dose of about 200 mg for about 30 minutes on day 1 of a 3-week cycle for up to 35 cycles.

[0385] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:79, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:80.

[0386] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:81; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:82; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:83; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:84; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:85; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:86.

[0387] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:79 and 80, respectively.

[0388] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 77 and 78, respectively.

[0389] In some embodiments, the method of the present disclosure comprises a combination of favezelimab and pembrolizumab. In some embodiments, 800mg of favezelimab and 200mg of pembrolizumab are administered intravenously on day 1, then about once every 3 weeks. In some embodiments, the combination of favezelimab and pembrolizumab is administered for up to 35 cycles. In some embodiments, 800mg of favezelimab and 200mg of pembrolizumab are administered intravenously for about 30 minutes on day 1 of a 3-week cycle, for up to 35 cycles.

[0390] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:69, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:70; and (b) an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:79, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:80.

[0391] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:71, SEQ ID NO:72, and SEQ ID NO:73, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:74, SEQ ID NO:75, and SEQ ID NO:76, respectively; and (b) an anti-PD-1 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:81, SEQ ID NO:82, and SEQ ID NO:83, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:84, SEQ ID NO:85, and SEQ ID NO:86, respectively.

[0392] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 69 and 70, respectively; and (b) an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 79 and 80, respectively.

[0393] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 67 and 68, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 77 and 78, respectively.

[0394] In some embodiments, the anti-PD-1 antibody is cemiplimab (REGN2810). Cemiplimab is described, for example, in WO2015 / 112800 and U.S. Patent No. 9,987,500.

[0395] In some embodiments, cemiplimab is administered intravenously at a dose of about 3 mg / kg or about 350 mg about once every three weeks.

[0396] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:35, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:36.

[0397] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:37; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:38; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:39; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:40; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:41; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:42.

[0398] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 35 and 36, respectively.

[0399] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 33 and 34, respectively.

[0400] In some embodiments, the methods of the disclosure include a combination of fianlimab and cemiplimab.

[0401] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:25, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:26; and (b) an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:35, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:36.

[0402] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, respectively; and (b) an anti-PD-1 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42, respectively.

[0403] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 25 and 26, respectively; and (b) an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 35 and 36, respectively.

[0404] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 23 and 24, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 33 and 34, respectively.

[0405] In some embodiments, the anti-PD-1 antibody is spartalizumab (PDR001). Spartalizumab is described, for example, in WO2015 / 112900 and U.S. Patent No. 9,683,048.

[0406] In some embodiments, spartalizumab is administered intravenously at a dose of about 300 mg once every about three weeks or 400 mg once every about four weeks.

[0407] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:59, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:60.

[0408] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising: (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:61; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:62; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:63; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:64; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:65; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:66.

[0409] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:59 and 60, respectively.

[0410] In some embodiments, the methods of the disclosure include an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs:57 and 58, respectively.

[0411] In some embodiments, the method of the present disclosure comprises a combination of yelamirimab and spartalizumab.In some embodiments, yelamirimab is administered intravenously at a dose of about 400mg once every about 3 weeks, and spartalizumab is administered intravenously at a dose of about 300mg once every about 3 weeks.In some embodiments, yelamirimab is administered intravenously at a dose of about 600mg once every about 4 weeks, and spartalizumab is administered intravenously at a dose of about 400mg once every about 4 weeks.

[0412] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:47, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:49, and (b) an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:59, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:60.

[0413] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:48, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:50; and (b) an anti-PD-1 antibody comprising the CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:59, and the CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:60.

[0414] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56, respectively; and (b) an anti-PD-1 antibody comprising heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:63, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, respectively.

[0415] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 47 and 49, respectively; and (b) an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 59 and 60, respectively.

[0416] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 48 and 50, respectively; and (b) an anti-PD-1 antibody comprising heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 59 and 60, respectively.

[0417] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 43 and 45, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 57 and 58, respectively.

[0418] In some embodiments, the methods of the disclosure include (a) an anti-LAG-3 antibody comprising a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 44 and 46, respectively, and (b) an anti-PD-1 antibody comprising a heavy chain and a light chain comprising the sequences as set forth in SEQ ID NOs: 57 and 58, respectively.

[0419] The anti-LAG-3 antibody and the anti-PD-1 antibody may be administered in any of the doses or combinations of doses described herein.

[0420] In some embodiments, the dose of anti-LAG-3 antibody is about 80 mg.

[0421] In some embodiments, the dose of anti-LAG-3 antibody is about 160 mg.

[0422] In some embodiments, the dose of anti-LAG-3 antibody is about 360 mg.

[0423] In some embodiments, the dose of anti-LAG-3 antibody is about 480 mg.

[0424] In some embodiments, the dose of anti-LAG-3 antibody is about 720 mg.

[0425] In some embodiments, the dose of anti-LAG-3 antibody is about 800 mg.

[0426] In some embodiments, the dose of anti-LAG-3 antibody is about 960 mg.

[0427] In some embodiments, the dose of the anti-PD-1 antibody is about 200 mg.

[0428] In some embodiments, the dose of the anti-PD-1 antibody is about 240 mg.

[0429] In some embodiments, the dose of the anti-PD-1 antibody is about 360 mg.

[0430] In some embodiments, the dose of the anti-PD-1 antibody is about 480 mg.

[0431] In some embodiments, the dose of the anti-LAG-3 antibody is about 80 mg and the dose of the anti-PD-1 antibody is about 240 mg.

[0432] In some embodiments, the dose of the anti-LAG-3 antibody is about 80 mg and the dose of the anti-PD-1 antibody is about 480 mg.

[0433] In some embodiments, the dose of the anti-LAG-3 antibody is about 160 mg and the dose of the anti-PD-1 antibody is about 480 mg.

[0434] In some embodiments, the dose of the anti-LAG-3 antibody is about 360 mg and the dose of the anti-PD-1 antibody is about 360 mg.

[0435] In some embodiments, the dose of the anti-LAG-3 antibody is about 480 mg and the dose of the anti-PD-1 antibody is about 480 mg.

[0436] In some embodiments, the dose of the anti-LAG-3 antibody is about 720 mg and the dose of the anti-PD-1 antibody is about 360 mg.

[0437] In some embodiments, the dose of the anti-LAG-3 antibody is about 800 mg and the dose of the anti-PD-1 antibody is about 200 mg.

[0438] In some embodiments, the dose of the anti-LAG-3 antibody is about 960 mg and the dose of the anti-PD-1 antibody is about 480 mg.

[0439] In some embodiments, the dose of the anti-LAG-3 antibody is about 2 mg / kg and the dose of the anti-PD-1 antibody is about 6 mg / kg.

[0440] In some embodiments, the dose of the anti-LAG-3 antibody is about 1 mg / kg and the dose of the anti-PD-1 antibody is about 6 mg / kg.

[0441] Provided herein is a method of treating a human subject with relapsed or refractory cHL, the method comprising administering to the subject (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody, (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody, (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody has a sequence set forth in SEQ ID NO:3. and CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:4, the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and the subject is about 12 years of age or older and weighs about 40 kg or more.

[0442] Provided herein is a method of treating a human subject with relapsed or refractory cHL, the method comprising administering to the subject (a) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and the subject has a body weight of less than about 40 kg, is less than about 12 years of age, or both.

[0443] Provided herein is a method of treating a human subject with relapsed or refractory NHL, the method comprising administering to the subject (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody, (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody, (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody has a sequence set forth in SEQ ID NO:3. and CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:4, the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and the subject is about 12 years of age or older and weighs about 40 kg or more.

[0444] Provided herein is a method of treating a human subject with relapsed or refractory non-Hodgkin's lymphoma, the method comprising administering to the subject (a) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, wherein the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4, and the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14, and the subject has a body weight of less than about 40 kg, is less than about 12 years of age, or both.

[0445] In some embodiments, (a) the anti-LAG-3 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively; and (b) the anti-PD-1 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:20, respectively.

[0446] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:13 and 14, respectively.

[0447] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chains comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the sequences as set forth in SEQ ID NOs: 11 and 12, respectively.

[0448] In some embodiments, the anti-LAG-3 antibody comprises heavy and light chains comprising the sequences set forth in SEQ ID NOs:21 and 2, respectively, and the anti-PD-1 antibody comprises heavy and light chains comprising the sequences as set forth in SEQ ID NOs:11 and 12, respectively.

[0449] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are administered about once every four weeks. In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are administered on day 1 of every four week cycle.

[0450] In some embodiments, the anti-LAG-3 antibody is administered intravenously over a period of about 30 minutes.

[0451] In some embodiments, the anti-PD-1 antibody is administered intravenously over a period of about 30 minutes.

[0452] In some embodiments, a pharmaceutical composition comprising an anti-LAG-3 antibody and an anti-PD-1 antibody is administered intravenously over a period of about 30 minutes.

[0453] II.B.1.a.ii. Anti-PD-L1 antibody Anti-PD-L1 antibodies known in the art can be used in the methods of the disclosure. Examples of anti-PD-L1 antibodies useful in the compositions and methods of the disclosure include the antibodies disclosed in U.S. Patent No. 9,580,507. The anti-PD-L1 human monoclonal antibody disclosed in U.S. Patent No. 9,580,507 has been demonstrated to exhibit one or more of the following characteristics: (a) a PD-L1 concentration of 1×10 as determined by surface plasmon resonance using a Biacore biosensor system; -7 K below M D(b) bind to human PD-L1 in a mixed lymphocyte reaction (MLR) assay; (c) increase interferon-γ production in an MLR assay; (d) increase IL-2 secretion in an MLR assay; (e) stimulate antibody responses; and (f) reverse the effects of regulatory T cells on T cell effector cells and / or dendritic cells. Anti-PD-L1 antibodies that can be used in the present disclosure include monoclonal antibodies that specifically bind to human PD-L1 and exhibit at least one, and in some embodiments at least five, of the foregoing characteristics.

[0454] Anti-PD-L1 antibodies that may be used in the methods of the disclosure include BMS-936559 (also known as 12A4, MDX-1105; see, e.g., U.S. Pat. No. 7,943,743 and WO 2013 / 173223), atezolizumab [Roche; also known as TECENTRIQ®; MPDL3280A, RG7446; see, U.S. Pat. No. 8,217,149; see also Herbst et al. (2013) J Clin Oncol 31(suppl):3000], durvalumab [AstraZeneca; also known as IMFINZI™, MEDI-4736; see WO2011 / 066389], avelumab [Pfizer; also known as BAVENCIO®, MSB-0010718C; see WO2013 / 079174], STI-1014 (Sorrento; see WO2013 / 181634), CX-072 (Cytomx; see WO2016 / 149201), KN035 [3D Med / Alphamab; see Zhang et al., Cell Discov. 7:3 (March 2017)], LY3300054 (Eli Lilly Co.; see, e.g., WO2017 / 034916), BGB-A333 [BeiGene; see Desai et al., JCO 36 (15suppl):TPS3113 (2018)], ICO 36, FAZ053 (Novartis), and CK-301 [Checkpoint Therapeutics; see Gorelik et al., AACR:Abstract 4606 (Apr 2016)].

[0455] Anti-PD-L1 antibodies that may be used in the methods of the disclosure also include isolated antibodies that specifically bind to human PD-L1 and cross-compete for binding to human PD-L1 with any of the anti-PD-L1 antibodies disclosed herein (e.g., atezolizumab, durvalumab, and / or avelumab). In some embodiments, the anti-PD-L1 antibody binds to the same epitope as any of the anti-PD-L1 antibodies described herein (e.g., atezolizumab, durvalumab, and / or avelumab). In certain embodiments, the antibody that cross-competes for binding to human PD-L1 or binds to the same epitope region as any of the anti-PD-L1 antibodies disclosed herein (e.g., atezolizumab, durvalumab, and / or avelumab) is a monoclonal antibody. For administration to human subjects, these cross-competing antibodies are chimeric, engineered, or humanized or human antibodies. Such chimeric, engineered, humanized, or human monoclonal antibodies can be prepared and isolated by methods well known in the art.

[0456] Anti-PD-L1 antibodies that may be used in the methods of the disclosure include antigen-binding portions of any of the full-length antibodies listed above.

[0457] The anti-PD-L1 antibodies that may be used in the methods of the present disclosure are those that bind to PD-L1 with high specificity and affinity, block the binding of PD-1, and inhibit the immunosuppressive effects of the PD-1 signaling pathway. In any of the compositions or methods disclosed herein, the anti-PD-L1 "antibody" includes an antigen-binding portion or fragment that binds to PD-L1 and exhibits functional properties similar to those of the whole antibody in inhibiting receptor binding and upregulating the immune system. In certain embodiments, the anti-PD-L1 antibody or antigen-binding portion thereof cross-competes with atezolizumab, durvalumab, and / or avelumab for binding to human PD-L1.

[0458] In some embodiments, the anti-PD-L1 antibody replaces the anti-PD-1 antibody in any of the methods disclosed herein.

[0459] In some embodiments, the anti-PD-L1 antibody is a full-length antibody.

[0460] In some embodiments, the anti-PD-L1 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, DVD-Ig, or a bispecific antibody.

[0461] In some embodiments, the anti-PD-L1 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, an scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide.

[0462] In some embodiments, the anti-PD-L1 antibody is BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, KN035, LY3300054, BGB-A333, ICO 36, FAZ053, CK-301, or comprises an antigen-binding portion thereof.

[0463] In some embodiments, the PD-L1 antibody is atezolizumab. Atezolizumab is a fully humanized IgG1 monoclonal anti-PD-L1 antibody. In some embodiments, atezolizumab is administered as a fixed dose of about 800 mg once every about two weeks. In some embodiments, atezolizumab is administered as a fixed dose of about 840 mg once every about two weeks.

[0464] In some embodiments, atezolizumab is administered intravenously at a dose of about 1,200 mg on day 1 of a 3-week cycle.

[0465] In some embodiments, atezolizumab is administered intravenously at a dose of about 1,200 mg on day 1 of a 3-week cycle, and bevacizumab is administered at a dose of about 15 mg / kg on day 1 of each cycle.

[0466] In some embodiments, the PD-L1 antibody is durvalumab. Durvalumab is a human IgG1 kappa monoclonal anti-PD-L1 antibody. In some embodiments, durvalumab is administered at a dose of about 10 mg / kg about once every two weeks. In some embodiments, durvalumab is administered at a dose of about 10 mg / kg about once every two weeks for up to 12 months. In some embodiments, durvalumab is administered at a flat dose of about 800 mg / kg about once every two weeks. In some embodiments, durvalumab is administered at a flat dose of about 1200 mg / kg about once every three weeks.

[0467] In some embodiments, the PD-L1 antibody is avelumab. Avelumab is a human IgG1 lambda monoclonal anti-PD-L1 antibody. In some embodiments, avelumab is administered as a fixed dose of about 800 mg about once every two weeks.

[0468] II.B.1.b. CTLA-4 inhibitors In some embodiments, the checkpoint inhibitors disclosed herein include a CTLA-4 inhibitor. In some embodiments, the CTLA-4 inhibitor is an anti-CTLA-4 antibody.

[0469] Anti-CTLA-4 antibodies that may be used in the methods of the present disclosure bind to human CTLA-4 and disrupt the interaction of CTLA-4 with the human B7 receptor. Because the interaction of CTLA-4 with B7 transmits a signal that leads to the inactivation of T cells that bear the CTLA-4 receptor, disruption of this interaction effectively induces, enhances, or prolongs the activation of such T cells, thereby inducing, enhancing, or prolonging an immune response.

[0470] A human monoclonal antibody that specifically binds to CTLA-4 with high affinity is disclosed in US Patent No. 6,984,720.Other anti-CTLA-4 monoclonal antibodies are described in, for example, US Patent Nos. 5,977,318, 6,051,227, 6,682,736, and 7,034,121, as well as International Publication Nos. WO2012 / 122444, WO2007 / 113648, WO2016 / 196237, and WO2000 / 037504, each of which is incorporated herein by reference in its entirety.The anti-CTLA-4 human monoclonal antibody disclosed in US Patent No. 6,984,720 has been demonstrated to exhibit one or more of the following characteristics: (a) a CTLA-4 affinity of at least about 10, as determined by Biacore analysis; 7 M -1 , or about 10 9 M -1 , or about 10 10 M -1 From 10 11 M -1 or higher equilibrium association constant (K a (b) specifically binds human CTLA-4 with a binding affinity reflected by at least about 10 3 , about 10 4 , or about 10 5 m -1 s -1 The dynamic association constant (k a );(c) at least about 10 3 , about 10 4 , or about 10 5 m -1 s -1 The dynamic dissociation constant (k d and (d) inhibit binding of CTLA-4 to B7-1 (CD80) and B7-2 (CD86). Anti-CTLA-4 antibodies useful for the present disclosure include monoclonal antibodies that specifically bind to human CTLA-4 and exhibit at least one, at least two, or at least three of the aforementioned characteristics.

[0471] Anti-CTLA-4 antibodies that may be used in the methods of the disclosure include ipilimumab (aka YERVOY®, MDX-010, 10D1; see U.S. Pat. No. 6,984,720), MK-1308 (Merck), AGEN-1884 (Agenus Inc.; see WO2016 / 196237), and tremelimumab (AstraZeneca; aka ticilimumab, CP-675,206; see WO2000 / 037504 and Ribas, Update Cancer Ther. 2(3): 133-39 (2007)).

[0472] In some embodiments, the anti-CTLA-4 antibody specifically binds to human CTLA-4 and cross-competes for binding to human CTLA-4 with any of the anti-CTLA-4 antibodies disclosed herein (e.g., ipilimumab and / or tremelimumab). In some embodiments, the anti-CTLA-4 antibody binds to the same epitope as any of the anti-CTLA-4 antibodies described herein (e.g., ipilimumab and / or tremelimumab).

[0473] In some embodiments, antibodies that cross-compete for binding to human CTLA-4 or bind to the same epitopic region as any of the anti-CTLA-4 antibodies disclosed herein (e.g., ipilimumab and / or tremelimumab) are monoclonal antibodies. For administration to human subjects, these cross-competing antibodies are chimeric, engineered, or humanized or human antibodies.

[0474] Anti-CTLA-4 antibodies that can be used in the methods of the disclosure include antigen-binding portions of any of the full-length antibodies described above.

[0475] In some embodiments, the anti-CTLA-4 antibody is a full-length antibody. In some embodiments, the anti-CTLA-4 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody. In some embodiments, the multispecific antibody is a DART, a DVD-Ig, or a bispecific antibody.

[0476] In some embodiments, the anti-CTLA-4 antibody is a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single chain binding polypeptide.

[0477] In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, MK-1308, AGEN-1884, or comprises an antigen-binding portion thereof.

[0478] In some embodiments, the anti-CTLA-4 antibody is ipilimumab. Ipilimumab is a fully human, IgG1 monoclonal antibody that blocks the binding of CTLA-4 to its B7 ligand, thereby stimulating T cell activation. In some embodiments, ipilimumab is administered at a dose of about 3 mg / kg once about every 3 weeks. In some embodiments, ipilimumab is administered at a dose of about 10 mg / kg once about every 3 weeks. In some embodiments, ipilimumab is administered at a dose of about 10 mg / kg once about every 12 weeks. In some embodiments, ipilimumab is administered in 4 doses. In some embodiments, ipilimumab is administered on day 1 of each cycle.

[0479] III. Pharmaceutical Compositions Therapeutic agents of the present disclosure may be configured as compositions, such as pharmaceutical compositions, containing the inhibitors, antibodies, and / or agents disclosed herein and a pharma- ceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.

[0480] In some embodiments, the carrier for the compositions containing the inhibitors, antibodies, and / or agents disclosed herein is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). In some embodiments, the carrier is suitable for non-parenteral, e.g., oral, administration. In some embodiments, subcutaneous injection is based on Halozyme Therapeutics' ENHANZE® drug delivery technology (see U.S. Patent No. 7,767,429, which is incorporated herein by reference in its entirety). ENHANZE® uses a combination of an antibody with a recombinant human hyaluronidase enzyme (rHuPH20), which removes the traditional limitations on the volume of biologics and drugs that can be delivered subcutaneously due to the extracellular matrix (see U.S. Patent No. 7,767,429). The pharmaceutical compositions of the present disclosure can include one or more pharma- ceutically acceptable salts, antioxidants, aqueous and non-aqueous carriers, and / or adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. In some embodiments, the pharmaceutical compositions of the disclosure may further comprise a recombinant human hyaluronidase enzyme, such as rHuPH20.

[0481] Treatment is continued as long as clinical benefit is observed or until unacceptable toxicity or disease progression occurs. Dosage and frequency vary depending on the half-life of the inhibitor, antibody, and / or agent in the subject. In general, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies, and non-human antibodies. Dosage and frequency can vary depending on whether the treatment is preventive or therapeutic. In preventive applications, typically, relatively low dosages are administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, relatively high dosages at relatively short intervals may be required until disease progression is reduced or terminated, preferably until the patient shows partial or complete improvement of disease symptoms. The patient can then be administered prophylaxis.

[0482] The actual dosage level of the active ingredient (i.e., inhibitor, antibody, and / or drug) in the pharmaceutical composition of the present disclosure can be varied to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and administration form without being excessively toxic to the patient. The dosage level selected will depend on various pharmacokinetic factors, including the activity of the particular composition of the present disclosure used, the route of administration, the time of administration, the rate of excretion of the particular compound used, the duration of treatment, other drugs, compounds and / or substances used in combination with the particular composition used, the age, sex, weight, disease state, general health and previous medical history of the patient being treated, and similar factors well known in the medical field. The composition of the present disclosure can be administered via one or more routes of administration using one or more of a variety of methods well known in the art. As will be understood by those skilled in the art, the route and / or form of administration will vary depending on the desired result.

[0483] Provided herein are pharmaceutical compositions comprising an anti-LAG-3 antibody and an anti-PD-1 antibody described herein, in any of the doses or combinations of doses described herein.

[0484] In some embodiments, the pharmaceutical composition is for treating a human subject having a hematological cancer as described herein.

[0485] In some embodiments, the method of treating a human subject having a hematological cancer as described herein comprises administering a pharmaceutical composition as described herein.

[0486] In some embodiments, the pharmaceutical composition comprises a dose of relatolimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is nivolumab.

[0487] In some embodiments, the pharmaceutical composition comprises a dose of favezelimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0488] In some embodiments, the pharmaceutical composition comprises a dose of fianlimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is cemiplimab.

[0489] In some embodiments, the pharmaceutical composition comprises a dose of yelamirimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is spartalizumab.

[0490] In some embodiments, the pharmaceutical composition comprises about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about The anti-LAG-3 antibody and the anti-PD-1 antibody are in a ratio of about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, or about 2:1.

[0491] In some embodiments, the pharmaceutical composition comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 1:6.

[0492] In some embodiments, the pharmaceutical composition comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 1:3.

[0493] In some embodiments, the pharmaceutical composition comprises about a 1:1 ratio of anti-LAG-3 antibody and anti-PD-1 antibody.

[0494] In some embodiments, the pharmaceutical composition comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 2:1.

[0495] In some embodiments, the pharmaceutical composition comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 4:1.

[0496] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg / mL, approximately 135 mg / mL, approximately 140 mg / mL, approximately 145 mg / mL, approximately 150 mg / mL, approximately 155 mg / mL, approximately 160 mg / mL, approximately 165 mg / mL, approximately 170 mg / mL, approximately 175 mg / mL, approximately 180 mg / mL, approximately 185 mg / mL, approximately 190 mg / mL , about 195 mg / mL, about 200 mg / mL, about 205 mg / mL, about 210 mg / mL, about 215 mg / mL, about 220 mg / mL, about 225 mg / mL, about 230 mg / mL, about 235 mg / mL, about 240 mg / mL, about 245 mg / mL, about 250 mg / mL, about 255 mg / mL, approximately 260 mg / mL, approximately 265 mg / mL, approximately 270 mg / mL, approximately 275 mg / mL, approximately 280 mg / mL, approximately 285 mg / mL, approximately 290 mg / mL, approximately 295 mg / mL, approximately 300 mg / mL, approximately 305 mg / mL, approximately 310 mg / mL, approximately 315 mg / mL , about 320 mg / mL, about 325 mg / mL, about 330 mg / mL, about 335 mg / mL, about 340 mg / mL, about 345 mg / mL, about 350 mg / mL, about 355 mg / mL, about 360 mg / mL, about 365 mg / mL, about 370 mg / mL, about 375 mg / mL, about 380 mg / mL, about 385 mg / mL, about 390 mg / mL, about 395 mg / mL, about 400 mg / mL, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, About 170mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg,about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, about 1200 mg, about 1210 mg, about 1220 mg, about 1230 mg, about 1240 mg, about 1250 mg, about 1260 mg, about 1270 mg, about 1280 mg, about 1290 mg, about 1300 mg, about 1310 mg, about 1320 mg, about 1330 mg, about 1340 mg, about 1350 mg, about 1360 mg, about 1370 mg, about 1380 mg, about 1390 mg, about 1400 mg, about 1410 mg, about 1420 mg, about 1430 mg, about 1440 mg, about 1450 mg, about 1460 mg, about 1470 mg, about 1480 mg, about 1490 mg, about 1500 mg, about 1510 mg, about 1520 mg, about 1530 mg, about 1540 mg, about 1550 mg, about 1560 mg, about 1570 mg, about 1580 mg, about 1590 mg, about 1600 mg, about 1610 mg, about 1620 mg, about 1630 mg, about 1640 mg, about 1650 mg, about 1660 mg, about 1670 mgAbout 1680 mg, about 1690 mg, about 1700 mg, about 1710 mg, about 1720 mg, about 1730 mg, about 1740 mg, about 1750 mg, about 1760 mg, about 1770 mg, or about 1780 mg.

[0497] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 25 mg / mL.

[0498] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 50 mg / mL.

[0499] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 150 mg / mL.

[0500] In some embodiments, the total amount of the anti-LAG-3 antibody and the anti-PD-1 antibody in the pharmaceutical composition is about 50 mg.

[0501] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 320 mg.

[0502] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 560 mg.

[0503] In some embodiments, the total amount of the anti-LAG-3 antibody and the anti-PD-1 antibody in the pharmaceutical composition is about 640 mg.

[0504] In some embodiments, the total amount of the anti-LAG-3 antibody and the anti-PD-1 antibody in the pharmaceutical composition is about 720 mg.

[0505] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 960 mg.

[0506] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 1000 mg.

[0507] In some embodiments, the total amount of the anti-LAG-3 antibody and the anti-PD-1 antibody in the pharmaceutical composition is about 1080 mg.

[0508] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the pharmaceutical composition is about 1440 mg.

[0509] In some embodiments, the pharmaceutical composition comprises about 10 mg / mL, about 12.5 mg / mL, about 15 mg / mL, about 17.5 mg / mL, about 20 mg / mL, about 22.5 mg / mL, about 25 mg / mL, about 27.5 mg / mL, about 30 mg / mL, about 32.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 42.5 mg / mL, about 45 mg / mL, about 47.5 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, About 125mg / mL, 130mg / mL, about 135mg / mL, about 140mg / mL, about 145mg / mL, about 150mg / mL, about 155mg / mL, about 160mg / mL, Approx. 165mg / mL, approx. 170mg / mL, approx. 175mg / mL, approx. 180mg / mL, approx. 185mg / mL, approx. 190mg / mL, approx. 195mg / mL, approx. 200mg / mL, About 7 mg, about 21 mg, about 40 mg, about 70 mg, about 80 mg, about 160 mg, about 200 mg, about 210 mg, about 300 mg, about 400 mg, about 480 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 960 mg, about 1000 mg, about 1100 mg, about 1200 mg, or about 1300 mg of anti-LAG-3 antibody.In some embodiments, the pharmaceutical composition comprises about 5 mg / mL, about 10 mg / mL, about 12.5 mg / mL, about 15 mg / mL, about 17.5 mg / mL, about 20 mg / mL, about 22.5 mg / mL, about 25 mg / mL, about 27.5 mg / mL, about 30 mg / mL, about 32.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 42.5 mg / mL, about 45 mg / mL, about 47.5 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, 130 mg / mL, about 135 mg / mL, about 140 mg / mL, about 145 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 10 mg, about 40 mg, about 100 mg, about 200 mg, about 240 mg, about 300 mg, about 350 mg, about 360 mg, about 400 mg, or about 480 mg of anti-PD-1 antibody.

[0510] In some embodiments, the pharmaceutical composition comprises about 12.5 mg / mL of an anti-LAG-3 antibody and about 37.5 mg / mL of an anti-PD-1 antibody.

[0511] In some embodiments, the pharmaceutical composition comprises about 20 mg / mL of an anti-LAG-3 antibody and about 5 mg / mL of an anti-PD-1 antibody.

[0512] In some embodiments, the pharmaceutical composition comprises about 75 mg / mL of an anti-LAG-3 antibody and about 75 mg / mL of an anti-PD-1 antibody.

[0513] In some embodiments, the pharmaceutical composition comprises about 100 mg / mL of an anti-LAG-3 antibody and about 50 mg / mL of an anti-PD-1 antibody.

[0514] In some embodiments, the pharmaceutical composition comprises about 80 mg of an anti-LAG-3 antibody and about 240 mg of an anti-PD-1 antibody.

[0515] In some embodiments, the pharmaceutical composition comprises about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0516] In some embodiments, the pharmaceutical composition comprises about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0517] In some embodiments, the pharmaceutical composition comprises about 360 mg of an anti-LAG-3 antibody and about 360 mg of an anti-PD-1 antibody.

[0518] In some embodiments, the pharmaceutical composition comprises about 480 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0519] In some embodiments, the pharmaceutical composition comprises about 720 mg of an anti-LAG-3 antibody and about 360 mg of an anti-PD-1 antibody.

[0520] In some embodiments, the pharmaceutical composition comprises about 800 mg of an anti-LAG-3 antibody and about 200 mg of an anti-PD-1 antibody.

[0521] In some embodiments, the pharmaceutical composition comprises about 960 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0522] In some embodiments, the pharmaceutical composition comprises about 5 mM to about 50 mM histidine, about 50 mM to about 300 mM sucrose, about 5 μM to about 1 mM diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA), and about 0.001% to about 1% (w / v) of a polysorbate or poloxamer (e.g., polysorbate 80 (PS80), polysorbate 20 (PS20), poloxamer 188 (PX188), or any combination thereof).

[0523] In some embodiments, the pharmaceutical composition comprises about 20 mM histidine, about 250 mM sucrose, about 50 μM DTPA, and 0.05% PS80.

[0524] In some embodiments, the pH of the pharmaceutical composition is about 5 to about 6.5. In some embodiments, the pH is about 5.3 to about 6.3. In some embodiments, the pH is 5.8. In some embodiments, the pH is 5.7.

[0525] Provided herein is a vial, syringe, or intravenous bag containing the pharmaceutical composition described herein. In some embodiments, the present disclosure includes an autoinjector containing the pharmaceutical composition described herein.

[0526] In some embodiments, the vial contains a pharmaceutical composition as described herein, and the vial further comprises a stopper and a closure. In some embodiments, the total volume of the vial is about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, about 10 mL, about 11 mL, about 12 mL, about 13 mL, about 14 mL, about 15 mL, about 16 mL, about 17 mL, about 18 mL, about 19 mL, or about 20 mL.

[0527] IV. Kits Also included within the scope of the invention are kits for treating a human subject with a hematological cancer comprising any of the antibodies, therapeutic agents, and / or anti-cancer therapies described herein.

[0528] Kits typically include labels and instructions indicating the use of the contents of the kit. The term "label" includes any writing, or recorded material supplied on or with the kit, or which otherwise accompanies the kit.

[0529] Provided herein is a kit for treating a human subject with a hematological cancer, the kit comprising: (a) a dose of an anti-LAG-3 antibody; (b) a dose of an anti-PD-1 antibody; and (c) instructions for using the anti-LAG-3 antibody and the anti-PD-1 antibody in a method for treating a human subject with a hematological cancer.

[0530] The anti-LAG-3 antibody and the anti-PD-1 antibody may be provided in any of the doses or combinations of doses described herein.

[0531] In some embodiments, the kit comprises a dose of relatolimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is nivolumab.

[0532] In some embodiments, the kit comprises a dose of favezelimab and a dose of an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0533] In some embodiments, the kit comprises fianlimab and an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is cemiplimab.

[0534] In some embodiments, the kit comprises yelamirimab and an anti-PD-1 antibody as described herein. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or spartalizumab. In some embodiments, the anti-PD-1 antibody is spartalizumab.

[0535] In some embodiments, the kit comprises about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 1:250, about 1:300, about 1:350, about 1:360, about 1:370, about 1:380, about 1:390, about 1:400, about 1:410, about 1:420, about 1:430, about 1:440, about 1:450, about 1:460, about 1:470, about 1:480, about 1:490, about 1:500, about 1:510, about 1:520, about 1:530, about 1:540, about 1:550, about 1:560, about 1:570, about 1:580, about 1:590, about 1:600, about 1:610, about 1:620, about 1:630, about 1:640, about 1:650, about 1:660, about 1:670, about 1:680, about 1:690, about 1:700, about 1:710, about 1:720, about 1:730, about 1: The anti-LAG-3 antibody and the anti-PD-1 antibody are preferably in a ratio of about 00:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, or about 2:1.

[0536] In some embodiments, the kit comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 1:6.

[0537] In some embodiments, the kit comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 1:3.

[0538] In some embodiments, the kit comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 1:1.

[0539] In some embodiments, the kit comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 2:1.

[0540] In some embodiments, the kit comprises an anti-LAG-3 antibody and an anti-PD-1 antibody in a ratio of about 4:1.

[0541] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 180 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 220 mg / mL, about 230 mg / mL, about 240 mg / mL, about 250 mg / mL, about 260 mg / mL, about 270 mg / mL, about 280 mg / mL, about 290 mg / mL, about 300 mg / mL, about 310 mg / mL, about 320 mg / mL, about 330 mg / mL, about 340 mg / mL, about 350 mg / mL, about 360 mg / mL, about 370 mg / mL, about 380 mg / mL, about 390 mg / mL, about 400 mg / mL, about 410 mg / mL, about 420 mg / mL, about 430 mg / mL, about 440 mg / mL, about 450 mg / mL, about 460 mg g / mL, approx. 135 mg / mL, approx. 140 mg / mL, approx. 145 mg / mL, approx. 150 mg / mL, approx. 155 mg / mL, approx. 160 mg / mL, approx. 165 mg / mL, approx. 170 mg / mL, approx. Approx. 195mg / mL, Approx. 200mg / mL, Approx. 205mg / mL, Approx. 210mg / mL, Approx. 215mg / mL, Approx. 220mg / mL, Approx. 225mg / mL, Approx. 230mg / mL, Approx. 235mg / mL, Approx. 240mg / mL, Approx. g / mL, approximately 260 mg / mL, approximately 265 mg / mL, approximately 270 mg / mL, approximately 275 mg / mL, approximately 280 mg / mL, approximately 285 mg / mL, approximately 290 mg / mL, approximately 295 mg / mL, approximately 300 mg / mL, approximately 305 mg / mL, approximately 310 mg / mL, approximately 315 mg / mL, Approx. 320 mg / mL, approx. 325 mg / mL, approx. 330 mg / mL, approx. 335 mg / mL, approx. 340 mg / mL, approx. 345 mg / mL, approx. 350 mg / mL, approx. 355 mg / mL, approx. 360 mg / mL, approx. 365 mg / mL, approx. 370 mg / mL, approx. g / mL, approximately 385 mg / mL, approximately 390 mg / mL, approximately 395 mg / mL, approximately 400 mg / mL, approximately 50 mg, approximately 60 mg, approximately 70 mg, approximately 80 mg, approximately 90 mg, approximately 100 mg, approximately 110 mg, approximately 120 mg, approximately 130 mg, approximately 140 mg, approximately 150 mg, approximately 160 mg, approximately 170mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg,about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 1020 mg, about 1030 mg, about 1040 mg, about 1050 mg, about 1060 mg, about 1070 mg, about 1080 mg, about 1090 mg, about 1100 mg, about 1110 mg, about 1120 mg, about 1130 mg, about 1140 mg, about 1150 mg, about 1160 mg, about 1170 mg, about 1180 mg, about 1190 mg, about 1200 mg, about 1210 mg, about 1220 mg, about 1230 mg, about 1240 mg, about 1250 mg, about 1260 mg, about 1270 mg, about 1280 mg, about 1290 mg, about 1300 mg, about 1310 mg, about 1320 mg, about 1330 mg, about 1340 mg, about 1350 mg, about 1360 mg, about 1370 mg, about 1380 mg, about 1390 mg, about 1400 mg, about 1410 mg, about 1420 mg, about 1430 mg, about 1440 mg, about 1450 mg, about 1460 mg, about 1470 mg, about 1480 mg, about 1490 mg, about 1500 mg, about 1510 mg, about 1520 mg, about 1530 mg, about 1540 mg, about 1550 mg, about 1560 mg, about 1570 mg, about 1580 mg, about 1590 mg, about 1600 mg, about 1610 mg, about 1620 mg, about 1630 mg, about 1640 mg, about 1650 mg, about 1660 mg, about 1670 mgAbout 1680 mg, about 1690 mg, about 1700 mg, about 1710 mg, about 1720 mg, about 1730 mg, about 1740 mg, about 1750 mg, about 1760 mg, about 1770 mg, or about 1780 mg.

[0542] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 25 mg / mL.

[0543] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 50 mg / mL.

[0544] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 150 mg / mL.

[0545] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 50 mg.

[0546] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 320 mg.

[0547] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 560 mg.

[0548] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 640 mg.

[0549] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 720 mg.

[0550] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 960 mg.

[0551] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 1000 mg.

[0552] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 1080 mg.

[0553] In some embodiments, the total amount of anti-LAG-3 antibody and anti-PD-1 antibody in the kit is about 1440 mg.

[0554] In some embodiments, the kit comprises a medicament for use in treating or preventing atopic dermatitis, comprising about 10 mg / mL, about 12.5 mg / mL, about 15 mg / mL, about 17.5 mg / mL, about 20 mg / mL, about 22.5 mg / mL, about 25 mg / mL, about 27.5 mg / mL, about 30 mg / mL, about 32.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 42.5 mg / mL, about 45 mg / mL, about 47.5 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125mg / mL, 130mg / mL, about 135mg / mL, about 140mg / mL, about 145mg / mL, about 150mg / mL, about 155mg / mL, about 160mg / mL, about 165mg / mL, about 170mg / mL, about 175mg / mL, about 180mg / mL, about 185mg / mL, about 190mg / mL, about 195mg / mL, about 200mg / mL, about 7 mg, about 21 mg, about 40 mg, about 70 mg, about 80 mg, about 160 mg, about 200 mg, about 210 mg, about 300 mg, about 400 mg, about 480 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 960 mg, about 1000 mg, about 1100 mg, about 1200 mg, or about 1300 mg of anti-LAG-3 antibody.In some embodiments, the kit comprises a medicament for use in treating or preventing atopic dermatitis, comprising about 5 mg / mL, about 10 mg / mL, about 12.5 mg / mL, about 15 mg / mL, about 17.5 mg / mL, about 20 mg / mL, about 22.5 mg / mL, about 25 mg / mL, about 27.5 mg / mL, about 30 mg / mL, about 32.5 mg / mL, about 35 mg / mL, about 37.5 mg / mL, about 40 mg / mL, about 42.5 mg / mL, about 45 mg / mL, about 47.5 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, about 100 mg / mL L, about 105 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, 130 mg / mL, about 135 mg / mL, about 140 mg / mL, about 145 mg / mL, about 150 mg / mL, about 155 mg / mL, about 160 mg / mL, about 165 mg / mL, about 170 mg / mL, about 175 mg / mL, about 180 mg / mL, about 185 mg / mL, about 190 mg / mL, about 195 mg / mL, about 200 mg / mL, about 10 mg, about 40 mg, about 100 mg, about 200 mg, about 240 mg, about 300 mg, about 350 mg, about 360 mg, about 400 mg, or about 480 mg of anti-PD-1 antibody.

[0555] In some embodiments, the kit comprises about 12.5 mg / mL of an anti-LAG-3 antibody and about 37.5 mg / mL of an anti-PD-1 antibody.

[0556] In some embodiments, the kit comprises about 20 mg / mL of an anti-LAG-3 antibody and about 5 mg / mL of an anti-PD-1 antibody.

[0557] In some embodiments, the kit comprises about 75 mg / mL of an anti-LAG-3 antibody and about 75 mg / mL of an anti-PD-1 antibody.

[0558] In some embodiments, the kit comprises about 100 mg / mL of an anti-LAG-3 antibody and about 50 mg / mL of an anti-PD-1 antibody.

[0559] In some embodiments, the kit comprises about 80 mg of an anti-LAG-3 antibody and about 240 mg of an anti-PD-1 antibody.

[0560] In some embodiments, the kit comprises about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0561] In some embodiments, the kit comprises about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0562] In some embodiments, the kit comprises about 360 mg of an anti-LAG-3 antibody and about 360 mg of an anti-PD-1 antibody.

[0563] In some embodiments, the kit comprises about 480 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0564] In some embodiments, the kit comprises about 720 mg of an anti-LAG-3 antibody and about 360 mg of an anti-PD-1 antibody.

[0565] In some embodiments, the kit comprises about 800 mg of an anti-LAG-3 antibody and about 200 mg of an anti-PD-1 antibody.

[0566] In some embodiments, the kit comprises about 960 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody.

[0567] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are co-packaged in a single unit dosage form.

[0568] In some embodiments, the anti-LAG-3 antibody and the anti-PD-1 antibody are packaged as separate unit dosage forms.

[0569] In some embodiments, about 40 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0570] In some embodiments, about 80 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0571] In some embodiments, about 160 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0572] In some embodiments, about 360 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0573] In some embodiments, about 480 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0574] In some embodiments, about 720 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0575] In some embodiments, about 800 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0576] In some embodiments, about 960 mg of anti-LAG-3 antibody is provided in a unit dosage form.

[0577] In some embodiments, about 12.5 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0578] In some embodiments, about 20 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0579] In some embodiments, about 50 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0580] In some embodiments, about 75 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0581] In some embodiments, about 100 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0582] In some embodiments, about 130 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0583] In some embodiments, about 150 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0584] In some embodiments, about 175 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0585] In some embodiments, about 200 mg / mL of anti-LAG-3 antibody is provided in a unit dosage form.

[0586] In some embodiments, about 10 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0587] In some embodiments, about 40 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0588] In some embodiments, about 100 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0589] In some embodiments, about 200 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0590] In some embodiments, about 240 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0591] In some embodiments, about 360 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0592] In some embodiments, about 480 mg of the anti-PD-1 antibody is provided in a unit dosage form.

[0593] In some embodiments, about 5 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0594] In some embodiments, about 10 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0595] In some embodiments, about 37.5 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0596] In some embodiments, about 50 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0597] In some embodiments, about 75 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0598] In some embodiments, about 100 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0599] In some embodiments, about 175 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0600] In some embodiments, about 200 mg / mL of the anti-PD-1 antibody is provided in a unit dosage form.

[0601] In some embodiments, the unit dosage form comprises about 5 mM to about 50 mM histidine, about 50 mM to about 300 mM sucrose, about 5 μM to about 1 mM diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA), and about 0.001% to about 1% (w / v) of a polysorbate or poloxamer (e.g., polysorbate 80 (PS80), polysorbate 20 (PS20), poloxamer 188 (PX188), or any combination thereof).

[0602] In some embodiments, the unit dosage form comprises about 20 mM histidine, about 250 mM sucrose, about 50 μM DTPA, and 0.05% PS80.

[0603] In some embodiments, the unit dosage form comprises a pH of about 5 to about 6.5. In some embodiments, the pH is about 5.3 to about 6.3. In some embodiments, the pH is 5.8. In some embodiments, the pH is 5.7.

[0604] In some embodiments, the unit dosage form is a vial, a syringe, or an intravenous bag. In some embodiments, the unit dosage form is an autoinjector. In some embodiments, the unit dosage form is a vial that includes a stopper and a seal. In some embodiments, the total volume of the vial is about 5mL, about 6mL, about 7mL, about 8mL, about 9mL, about 10mL, about 11mL, about 12mL, about 13mL, about 14mL, about 15mL, about 16mL, about 17mL, about 18mL, about 19mL, or about 20mL.

[0605] In some embodiments, the kit provides instructions for administering the anti-LAG-3 antibody and / or the anti-PD-1 antibody intravenously over a period of about 30 minutes.

[0606] All of the references cited above, as well as all references cited herein, are incorporated herein by reference in their entirety.

[0607] The following examples are offered by way of illustration and not by way of limitation. EXAMPLES

[0608] [Example 1]

[0609] Combination of anti-LAG-3 and anti-PD-1 antibodies for treating hematological cancers This open-label clinical trial will evaluate the safety and tolerability of the combination of leratolimab and nivolumab in participants with relapsed or refractory (R / R) classical Hodgkin lymphoma (cHL) or R / R non-Hodgkin lymphoma (NHL). The study will be conducted in two parts. Part A will characterize the safety, tolerability, and pharmacokinetics of leratolimab + nivolumab in pediatric participants aged 18 years or younger with R / R cHL or R / R NHL and define the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part A will include a fixed dosing cohort (AF) for participants aged 12 years or older and weighing 40 kg or more, and a weight-based dosing cohort (AW) for participants aged 12 years or older and / or weighing less than 40 kg. Part B includes an expansion cohort (Cohort 1) to evaluate the preliminary efficacy of leratolimab + nivolumab based on the RP2D from Part A in participants aged ≤30 years with R / R cHL, and an exploratory cohort (Cohort 2) to evaluate the efficacy of leratolimab + nivolumab in participants with R / R NHL.

[0610] Participant Inclusion / Exclusion Criteria The study included male and female participants aged ≤18 years (Part A) and ≤30 years (Part B) with pathologically confirmed high-risk R / R cHL or high-risk R / R NHL after failure or non-response to first-line therapy and prior to high-dose chemotherapy (HDCT) / autologous stem cell transplant (ASCT).

[0611] Accepted stages of cHL include stage IIB with bulky disease, IIIA, IIIB and IV with E-lesions with or without bulky disease, where E-lesions are defined as local involvement of extranodal tissue (by contiguous growth from or in close anatomical relationship to an involved lymph node) treatable by radiation. High risk of cHL in this study is defined by the following features: early relapse, extranodal disease or B symptoms at the time of relapse, extensive disease where radiation therapy was contraindicated at the time of relapse, and / or relapse in a previous radiation field.

[0612] Accepted NHL stages include stage III or stage IV according to the Lugano 2014 classification. NHL includes, but is not limited to, diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), and primary mediastinal B-cell lymphoma. High risk NHL in this study is defined by Karnofsky performance status <80%, elevated serum lactate dehydrogenase, and a score of ≥2 on the second-line Age-Adjusted International Prognostic Index (sAAIPI) scale, which assigns a score of 1 point each to stage III / IV disease.

[0613] For both cHL and NHL, recurrent (or relapsing) disease is defined as achieving a complete response (CR) to prior therapy but progressing more than 3 months after completion of that therapy, whereas refractory disease is defined as never achieving a CR to prior therapy or achieving a CR but progressing within 3 months of completion of that therapy.

[0614] Participants must have measurable or evaluable disease based on the Lugano 2014 classification criteria, and two-dimensional measurable disease with high uptake on [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) and at least 1.5 cm in its longest axis as documented by radiographic techniques [e.g., contrast-enhanced computed tomography (CT)].

[0615] The Lansky Play Performance Scale and Karnofsky Performance Score for participants 16 years of age or younger and over 16 years of age must each be assessed within 2 weeks of enrollment and be equal to or greater than 60. Participants who are non-ambulatory due to neurological deficits but who are in a wheelchair will be considered ambulatory for the purposes of assessing performance scores.

[0616] Participants must have achieved substantial recovery from prior therapy (i.e., grade 1 or less or no ongoing safety issues).

[0617] Formalin-fixed, paraffin-embedded tissue blocks or a minimum of 20 unstained slides of tumor tissue from core biopsy, punch biopsy, excision biopsy, or surgical specimen will be obtained during screening or prior to treatment allocation within 3 months of enrollment, and there will be no intervening systemic anti-cancer treatment between the time of acquisition and enrollment.

[0618] The main exclusion criteria were: (1) previous treatment with anti-CTLA-4 antibodies or any other antibodies or drugs that specifically target T cell costimulatory or checkpoint pathways (excluding anti-PD-1 or anti-PD-L1 targeted therapies); (2) previous treatment with a LAG-3 targeting agent; (3) participants with a history of HDCT / ASCT; (4) participants with a history of allogeneic bone marrow transplant and active graft-versus-host disease (GVHD) and a history of GVHD greater than grade 2; (5) participants with clinically significant systemic illness unrelated to cancer, as determined by the investigator, that would impair the participant's ability to tolerate the study treatment; and (6) participants with an autoimmune disease.

[0619] Part A Pediatric participants aged ≤18 years with R / R cHL or R / R NHL will be recruited and assigned to either fixed dosing (AF) or weight-based dosing (AW) cohorts.

[0620] AF Cohort: Up to 6 participants aged ≥12 and <18 years weighing at least 40 kg will receive fixed doses of 160 mg relatolimab (BMS-986016) and 480 mg nivolumab (BMS-936558) intravenously (IV) every 4 weeks (Q4W) (i.e., A1F). If the starting dose is found to be not tolerated, the dose of relatolimab will be reduced to 80 mg in combination with nivolumab 480 mg (IV Q4W) (i.e., A2F).

[0621] AW cohort: Up to 6 participants <12 years of age and / or weighing <40 kg will receive weight-based doses of 2 mg / kg up to 160 mg of relatolimab and 6 mg / kg up to 480 mg of nivolumab IV Q4W (i.e., A1W). If the starting doses are found to be not tolerated, the dose of relatolimab will be reduced to 1 mg / kg in combination with nivolumab 6 mg / kg IV Q4W (i.e., A2W).

[0622] Relatolimab will be mixed with nivolumab in the same infusion bag and co-administered intravenously over approximately 30 minutes at the prescribed dose for each cohort.

[0623] Enrollment into the two dosing cohorts (A1F and A1W) will begin in parallel. Safety and pharmacokinetic assessments in the two dosing cohorts will be performed simultaneously and independently of each other.

[0624] Dose-limiting toxicities (DLT) will be defined based on the incidence, intensity, and duration of adverse events (AEs) without clearly identified alternative causes to guide decisions regarding dose reduction. The DLT period will begin on day 1 and end on day 28 of cycle 1 (4-week period). AE severity will be graded according to the National Cancer Institute (NCI) CTCAE v5.0.

[0625] Because the dosing cohorts are independent, they will be evaluated separately for DLTs. If dosing in one cohort needs to be reduced or stopped due to a DLT, the other cohort will continue as outlined. If DLTs are observed in two or more participants in a cohort, the dose will be reduced for that cohort as above, and an additional six participants will be evaluated for toxicity and exposure for two or more DLTs.

[0626] If the A1F and A2F dose levels are not tolerated, recruitment into the AF cohort will be terminated. Additional participants aged 12 years or older and weighing at least 40 kg will be enrolled in the weight-based dosing cohort A2W and, if found to be tolerated, A2W will be declared the RP2D for these participants. Participants younger than 12 years and / or weighing less than 40 kg will continue to be enrolled and evaluated in parallel.

[0627] If no DLTs are observed, a minimum of 6 participants will be enrolled in A1F and A1W, respectively.

[0628] Part B Part B of the study will evaluate the efficacy of relatolimab and nivolumab at the RP2D / MTD from Part A in pediatric participants with high-risk R / R cHL (Cohort 1) and in a cohort of high-risk R / R NHL (Cohort 2). Participants in Part A will count toward the recruitment goal for Part B if they are treated with the same dose selected for Part B.

[0629] Male and female participants aged 30 years or younger with R / R cHL (Cohort 1) or NHL (Cohort 2) will be recruited.

[0630] Approximately 40 response-evaluable cHL participants will be enrolled in Cohort 1. Preliminary efficacy in cHL will be assessed using estimated complete metabolic response (CMR) rates and exact two-sided 90% confidence intervals (CIs) in the 40 response-evaluable participants. A retrospective analysis of response by LAG-3 expression will also be performed to evaluate the correlation between LAG-3 expression and CMR.

[0631] Exploratory efficacy evaluation of NHL in cohort 2 using CMR rates is based on a modified Simon's two-stage design: 10 response-evaluable participants are enrolled in stage 1. Further enrollment in cohort 2 is terminated if fewer than 2 / 10 responses are observed in stage 1. If at least 2 responses are observed in stage 1, retrospective analysis of LAG-3 expression among the first 10 response-evaluable participants and its correlation with clinical response will inform further recruitment of additional NHL participants into stage 2.

[0632] Participants on any tolerated dosing scheme in Part A and additional participants in Part B will be treated until PMD, death, unacceptable toxicity, symptomatic progression, investigator decision to discontinue treatment (e.g., due to CMR progressing the participant to HDCT / ASCT), participant decision to discontinue treatment or withdraw consent, participant loss to follow-up, end of study, or up to 2 years of treatment, whichever occurs first.

[0633] For efficacy evaluation in parts A and B, imaging and response criteria will be based on the revised recommendations by the International Lymphoma Working Group for malignant lymphomas. Primary response assessment will be assessed using the Lugano 2014 classification. Overall response rate (ORR) outcomes will be summarized using frequency tables with 95% CI. Distributions of time to event [e.g., progression-free survival (PFS), duration of response (DOR), and duration of CMR (DoCMR)] and time-point rates (e.g., PFS rate at 12 months) will be estimated using or derived by the Kaplan-Meier (KM) method, as appropriate. Overall survival (OS) data will be analyzed similarly to the PFS data analysis.

[0634] array SEQ ID NO:1 Heavy chain amino acid sequence; Anti-LAG-3 mAb (BMS-986016) QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWG QGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT ISKAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO:2 Light chain amino acid sequence; Anti-LAG-3 mAb (BMS-986016) EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:3 Heavy chain variable region (VH) amino acid sequence; Anti-LAG-3 mAb (BMS-986016) QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS SEQ ID NO: 4 Light chain variable region (VL) amino acid sequence; Anti-LAG-3 mAb (BMS-986016) EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK SEQ ID NO:5 Heavy chain CDR1 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) DYYWN SEQ ID NO:6 Heavy chain CDR2 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) EINHRGSTNSNPSLKS SEQ ID NO: 7 Heavy chain CDR3 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) GYSDYEYNWFDP SEQ ID NO:8 Light chain CDR1 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) RASQSISSYLA SEQ ID NO: 9 Light chain CDR2 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) DASNRAT SEQ ID NO: 10 Light chain CDR3 amino acid sequence; Anti-LAG-3 mAb (BMS-986016) QQRSNWPLT SEQ ID NO:11 Heavy chain amino acid sequence; Anti-PD-1 mAb (BMS-936558) QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO:12 Light chain amino acid sequence; Anti-PD-1 mAb (BMS-936558) EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:13 Heavy chain variable region (VH) amino acid sequence; Anti-PD-1 mAb (BMS-936558) QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS SEQ ID NO:14: Light chain variable region (VL) amino acid sequence; Anti-PD-1 mAb (BMS-936558) EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK SEQ ID NO: 15 Heavy chain CDR1 amino acid sequence; Anti-PD-1 mAb (BMS-936558) NSGMH SEQ ID NO: 16 Heavy chain CDR2 amino acid sequence; Anti-PD-1 mAb (BMS-936558) VIWYDGSKRYYADSVKG SEQ ID NO: 17 Heavy chain CDR3 amino acid sequence; Anti-PD-1 mAb (BMS-936558) NDDY SEQ ID NO:18 Light chain CDR1 amino acid sequence; Anti-PD-1 mAb (BMS-936558) RASQSVSSYLA SEQ ID NO: 19 Light chain CDR2 amino acid sequence; Anti-PD-1 mAb (BMS-936558) DASNRAT SEQ ID NO: 20 Light chain CDR3 amino acid sequence; Anti-PD-1 mAb (BMS-936558) QQSSNWPRT SEQ ID NO:21 Heavy chain amino acid sequence; Anti-LAG-3 mAb (BMS-986016) without terminal lysine QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWG QGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO:22 Lymphocyte activation gene 3 protein amino acid sequence (Homo Sapiens, NP_002277) MWEAQFLGLLFLQPLWVAPVKPLQPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGD FSLWLRPARRADAGEYRAAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQGRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTYRDGFNVSIMYNLTVLGL EPPTPLTVYAGAGSRVGLPCRLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLRLEDVSQAQAGTYTCHIHLQEQQLNATVTLAITVTPKSFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSF SGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTELSSPGAQRSGRAPGALPAGHLLLFLILGVLSLLLLVTGAFGFHLWRRQWRPRRFSALEQGIHPPQAQSKIEELEQEPEPEPEPEPEPEPEPEPEQL SEQ ID NO:23 Heavy chain amino acid sequence; Anti-LAG-3 mAb (REGN3767) QVQLVESGGGVVQPGRSLRLSCVASGTFFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYY ADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQEEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQ EGNVFSCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO: 24 Light chain amino acid sequence; Anti-LAG-3 mAb (REGN3767) EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPA RFSGSGTGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 25 Heavy chain variable region (VH) amino acid sequence; Anti-LAG-3 mAb (REGN3767) QVQLVESGGGVVQPGRSLRLSCVASGTFFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYY ADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVT VSS SEQ ID NO: 26 Light chain variable region (VL) amino acid sequence; Anti-LAG-3 mAb (REGN3767) EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPA RFSGSGTGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK SEQ ID NO: 27 Heavy chain CDR1 amino acid sequence; Anti-LAG-3 mAb (REGN3767) GFTFSSYG SEQ ID NO:28 Heavy chain CDR2 amino acid sequence; Anti-LAG-3 mAb (REGN3767) IWYDGSNK SEQ ID NO: 29 Heavy chain CDR3 amino acid sequence; Anti-LAG-3 mAb (REGN3767) ASVATSGDFDYYGMDV SEQ ID NO: 30 Light chain CDR1 amino acid sequence; Anti-LAG-3 mAb (REGN3767) QRISTY SEQ ID NO: 31 Light chain CDR2 amino acid sequence; Anti-LAG-3 mAb (REGN3767) DAS SEQ ID NO: 32 Light chain CDR3 amino acid sequence; Anti-LAG-3 mAb (REGN3767) QQRSNWPLT SEQ ID NO:33 Heavy chain amino acid sequence; Anti-PD-1 mAb (REGN2810) EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYF ADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQEEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF SCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO:34 Light chain amino acid sequence; Anti-PD-1 mAb (REGN2810) DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPS RFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFFGPGTVVDFRRTVAAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 35 Heavy chain variable region (VH) amino acid sequence; Anti-PD-1 mAb (REGN2810) EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYF ADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS SEQ ID NO: 36: Light chain variable region (VL) amino acid sequence; Anti-PD-1 mAb (REGN2810) DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPS RFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFFGPGTVVDFR SEQ ID NO: 37 Heavy chain CDR1 amino acid sequence; Anti-PD-1 mAb (REGN2810) GFTFSNFG SEQ ID NO: 38 Heavy chain CDR2 amino acid sequence; Anti-PD-1 mAb (REGN2810) ISGGGRDT SEQ ID NO: 39 Heavy chain CDR3 amino acid sequence; Anti-PD-1 mAb (REGN2810) VKWGNIYFDY SEQ ID NO: 40 Light chain CDR1 amino acid sequence; Anti-PD-1 mAb (REGN2810) LSINTF SEQ ID NO: 41 Light chain CDR2 amino acid sequence; Anti-PD-1 mAb (REGN2810) AAS SEQ ID NO: 42 Light chain CDR3 amino acid sequence; Anti-PD-1 mAb (REGN2810) QQSSNTPFT SEQ ID NO: 43 Heavy chain amino acid sequence; Anti-LAG-3 mAb (LAG525) QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTY ADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQ EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS RWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 44 Heavy chain amino acid sequence; Anti-LAG-3 mAb (LAG525) QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQAPGQGLEWMGWINTDTGEPTY ADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTT VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQ EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS RWQEGNVFSCSVMHEALHNHYTQKSLSLSLG SEQ ID NO: 45 Light chain amino acid sequence; Anti-LAG-3 mAb (LAG525) DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 46 Light chain amino acid sequence; Anti-LAG-3 mAb (LAG525) DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYQQKPGKAPKLLIYYTSTLHLGIPP RFSGSGYGTDFTLTINNIESEDAAYYFCQQYYNLPWTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 47 Heavy chain variable region (VH) amino acid sequence; Anti-LAG-3 mAb (LAG525) QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTY ADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTT VTVSS SEQ ID NO: 48 Heavy chain variable region (VH) amino acid sequence; Anti-LAG-3 mAb (LAG525) QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQAPGQGLEWMGWINTDTGEPTY ADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTT VTVSS SEQ ID NO: 49 Light chain variable region (VL) amino acid sequence; Anti-LAG-3 mAb (LAG525) DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK SEQ ID NO:50 Light chain variable region (VL) amino acid sequence; Anti-LAG-3 mAb (LAG525) DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYQQKPGKAPKLLIYYTSTLHLGIPP RFSGSGYGTDFTLTINNIESEDAAYYFCQQYYNLPWTFGQGTKVEIK SEQ ID NO:51 Heavy chain CDR1 amino acid sequence; Anti-LAG-3 mAb (LAG525) NYGMN SEQ ID NO:52 Heavy chain CDR2 amino acid sequence; Anti-LAG-3 mAb (LAG525) WINTDTGEPTYADDFKG SEQ ID NO:53 Heavy chain CDR3 amino acid sequence; Anti-LAG-3 mAb (LAG525) NPPYYYGTNNAEAMDY SEQ ID NO:54 Light chain CDR1 amino acid sequence; Anti-LAG-3 mAb (LAG525) SSSQDISNYLN SEQ ID NO: 55 Light chain CDR2 amino acid sequence; Anti-LAG-3 mAb (LAG525) YTSTLHL SEQ ID NO:56 Light chain CDR3 amino acid sequence; Anti-LAG-3 mAb (LAG525) QQYYNLPWT SEQ ID NO:57 Heavy chain amino acid sequence; Anti-PD-1 mAb (PDR001) EVQLVQSGAEVKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNF DEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSSAST KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQEEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF SCSVMHEALHNHYTQKSLSLSLG SEQ ID NO:58 Light chain amino acid sequence; Anti-PD-1 mAb (PDR001) EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTR ESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:59 Heavy chain variable region (VH) amino acid sequence; Anti-PD-1 mAb (PDR001) EVQLVQSGAEVKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNF DEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS SEQ ID NO:60 Light chain variable region (VL) amino acid sequence; Anti-PD-1 mAb (PDR001) EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTR ESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK SEQ ID NO: 61 Heavy chain CDR1 amino acid sequence; Anti-PD-1 mAb (PDR001) TYWMH SEQ ID NO: 62 Heavy chain CDR2 amino acid sequence; Anti-PD-1 mAb (PDR001) NIYPGTGGSNFDEKFKN SEQ ID NO: 63 Heavy chain CDR3 amino acid sequence; Anti-PD-1 mAb (PDR001) WTTTGAY SEQ ID NO:64 Light chain CDR1 amino acid sequence; Anti-PD-1 mAb (PDR001) KSSQSLLDSGNQKNFLT SEQ ID NO: 65 Light chain CDR2 amino acid sequence; Anti-PD-1 mAb (PDR001) WASTRES SEQ ID NO: 66 Light chain CDR3 amino acid sequence; Anti-PD-1 mAb (PDR001) QNDYSYPYT SEQ ID NO:67 Heavy chain amino acid sequence; Anti-LAG-3 mAb (MK4280) QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIY AQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSSA STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQEEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN VFSCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO:68 Light chain amino acid sequence; Anti-LAG-3 mAb (MK4280) DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLES GVPDRFSGSGSGTDFTLKISRVEAEEDVGVYYCQQSTEDPRTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 69 Heavy chain variable region (VH) amino acid sequence; Anti-LAG-3 mAb (MK4280) QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIY AQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS SEQ ID NO: 70 Light chain variable region (VL) amino acid sequence; Anti-LAG-3 Anti-LAG-3 mAb (MK4280) DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLES GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK SEQ ID NO: 71 Heavy chain CDR1 amino acid sequence; Anti-LAG-3 mAb (MK4280) DYNVD SEQ ID NO: 72 Heavy chain CDR2 amino acid sequence; Anti-LAG-3 mAb (MK4280) DINPNDGGTIYAQKFQE SEQ ID NO: 73 Heavy chain CDR3 amino acid sequence; Anti-LAG-3 mAb (MK4280) NYRWFGAMDH SEQ ID NO: 74 Light chain CDR1 amino acid sequence; Anti-LAG-3 mAb (MK4280) KASQSLDYEGDSDMN SEQ ID NO: 75 Light chain CDR2 amino acid sequence; Anti-LAG-3 mAb (MK4280) GASNLES SEQ ID NO: 76 Light chain CDR3 amino acid sequence; Anti-LAG-3 mAb (MK4280) QQSTEDPRT SEQ ID NO: 77 Heavy chain amino acid sequence; Anti-PD-1 mAb (MK3475) QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNF NEKFKNRVTLTTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPSQEEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG NVFSCSVMHEALHNHYTQKSLSLSLGK SEQ ID NO:78 Light chain amino acid sequence; Anti-PD-1 mAb (MK3475) EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLES GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:79 Heavy chain variable region (VH) amino acid sequence; Anti-PD-1 mAb (MK3475) QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNF NEKFKNRVTLTTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS SEQ ID NO:80 Light chain variable region (VL) amino acid sequence; Anti-PD-1 mAb (MK3475) EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLES GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGGTKVEIK SEQ ID NO: 81 Heavy chain CDR1 amino acid sequence; Anti-PD-1 mAb (MK3475) NYYMY SEQ ID NO:82 Heavy chain CDR2 amino acid sequence; Anti-PD-1 mAb (MK3475) GINPSNGGTNFNEKFKN SEQ ID NO:83 Heavy chain CDR3 amino acid sequence; Anti-PD-1 mAb (MK3475) RDYRFDMGFDY SEQ ID NO:84 Light chain CDR1 amino acid sequence; Anti-PD-1 mAb (MK3475) RASKGVSTSGYSYLH SEQ ID NO:85 Light chain CDR2 amino acid sequence; Anti-PD-1 mAb (MK3475) LASYLES SEQ ID NO:86 Light chain CDR3 amino acid sequence; Anti-PD-1 mAb (MK3475) QHSRDLPLT

Claims

1. A pharmaceutical composition comprising a lymphocyte-activation gene 3 (LAG-3) antagonist for use in treating a hematological cancer in a human subject, comprising: The object is (a) is about 12 years of age or older and weighs about 40 kg or more; (b) has a body weight of less than about 40 kg; or (c) is under about 12 years of age; Pharmaceutical compositions.

2. (a) The treatment is a primary therapy; (b) the treatment is a second-line therapy; (c) the treatment is a third-line therapy; (d) the subject has progressed on a previous therapy. (e) the subject is naive to a previous immuno-oncology therapy, or the subject is naive to a previous immuno-oncology therapy for a hematological cancer, or the hematological cancer is naive to a previous immuno-oncology therapy; (f) the LAG-3 antagonist is for administration to a subject prior to high-dose chemotherapy, autologous stem cell transplant, or a combination thereof; or (g) the subject is naive to prior high-dose chemotherapy, autologous stem cell transplant, or a combination thereof; The pharmaceutical composition of claim 1.

3. 10. The pharmaceutical composition of claim 1, wherein the hematological cancer is relapsed or refractory and / or the hematological cancer is metastatic.

4. 10. The pharmaceutical composition of claim 1, wherein the hematological cancer comprises leukemia, lymphoma, or myeloma. (a) the hematological cancer comprises Hodgkin's lymphoma; (b) the hematological cancer comprises non-Hodgkin's lymphoma; or (c) the hematological cancer comprises acute myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, myeloproliferative neoplasm, systemic mastocytosis, prolymphocytic leukemia, large granular lymphocytic leukemia, or blastic plasmacytoid dendritic cell neoplasm; The pharmaceutical composition of claim 1.

6. 6. The pharmaceutical composition of claim 5, wherein the Hodgkin's lymphoma comprises nodular lymphocyte-predominant Hodgkin's lymphoma or classical Hodgkin's lymphoma.

7. the classical Hodgkin lymphoma is relapsed or refractory classical Hodgkin lymphoma characterized by early relapse, B symptoms at relapse, extensive disease in contraindicated radiation therapy fields, relapse in previous radiation therapy fields, or a combination thereof; and / or The classical Hodgkin lymphoma is stage IIB with bulky disease, IIIA with E disease with or without bulky disease, IIIB, or IV; The pharmaceutical composition according to claim 6.

8. 6. The pharmaceutical composition of claim 5, wherein the non-Hodgkin's lymphoma comprises diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, central nervous system lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, primary mediastinal large B-cell lymphoma, adult T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Waldenstrom's macroglobulinemia, mycosis fungoides, or Sézary syndrome.

9. one or more immune cells in the subject's tumor tissue express LAG-3, and / or one or more tumor cells in the tumor tissue of the subject express PD-L1; The pharmaceutical composition of claim 1. (a) at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the immune cells express LAG-3; and / or (b) at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the tumor cells express PD-L1; The pharmaceutical composition of claim 9.

11. 2. The pharmaceutical composition of claim 1, wherein the LAG-3 antagonist comprises an anti-LAG-3 antibody and / or a soluble LAG-3 polypeptide. (a) the anti-LAG-3 antibody is a full-length antibody; (b) the anti-LAG-3 antibody is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody; or (c) the anti-LAG-3 antibody is F(ab') ２ a fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide, The pharmaceutical composition of claim 11.

13. The anti-LAG-3 antibody (a) BMS-986016 (leratolimab), IMP731 (H5L7BW), MK4280 (28G-10, favezelimab), REGN3767 (fianlimab), GSK2831781, humanized BAP050, IMP-701 (LAG525, yelamilimab), aLAG3 (0414), aLAG3 (0416), Sym022, TSR-033; TSR-075, XmAb841 (XmAb22841), MGD013 (tebotelimab), BI754111, FS118, P13B02-30, AVA-017, 25F7, AGEN1746, RO7247669, INCAGN02385, IBI-110, EMB-02, IBI-323, LBL-007, ABL501, or an antigen-binding portion thereof; (b) the CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and the CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4; (c) heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 5, 6, and 7, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 8, 9, and 10, respectively; (d) heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 3 and 4, respectively; (e) a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively; or (f) heavy and light chains comprising the sequences set forth in SEQ ID NOs: 21 and 2, respectively; 12. The pharmaceutical composition of claim 11, comprising:

14. The pharmaceutical composition of claim 11, wherein the soluble LAG-3 polypeptide comprises IMP321 (eftiragimodo alfa).

15. The pharmaceutical composition of any one of claims 1 to 14, further combined with a tyrosine kinase inhibitor, an antiangiogenic agent, a checkpoint inhibitor, a checkpoint stimulator, a chemotherapeutic agent, an immunotherapeutic agent, a platinum agent, an alkylating agent, a taxane, a nucleoside analog, an antimetabolite, a topoisomerase inhibitor, an anthracycline, a vinca alkaloid, or any combination thereof.

16. The checkpoint inhibitors include programmed death 1 (PD-1) pathway inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, T-cell immunoglobulin and ITIM domain (TIGIT) inhibitors, T-cell immunoglobulin mucin domain-containing molecule 3 (TIM-3) inhibitors, TIM-1 inhibitors, TIM-4 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, B- and T-cell lymphocyte attenuator (BTLA) inhibitors, V-domain Ig suppressor of T-cell activation (VISTA) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors, nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2) inhibitors, killer cell immunoglobulin-like receptor (KIR) inhibitors, adenosine A2a receptor (A2aR) inhibitors, transforming 16. The pharmaceutical composition of claim 15, comprising a transforming growth factor beta (TGF-β) inhibitor, a phosphoinositide 3-kinase (PI3K) inhibitor, a CD47 inhibitor, a CD48 inhibitor, a CD73 inhibitor, a CD113 inhibitor, a sialic acid-binding immunoglobulin-like lectin 7 (SIGLEC-7) inhibitor, a SIGLEC-9 inhibitor, a SIGLEC-15 inhibitor, a glucocorticoid-inducible TNFR-related protein (GITR) inhibitor, a galectin-1 inhibitor, a galectin-9 inhibitor, a carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) inhibitor, a G protein-coupled receptor 56 (GPR56) inhibitor, a repeat-dominant glycoprotein A (GARP) inhibitor, a 2B4 inhibitor, a programmed death 1 homolog (PD1H) inhibitor, a leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) inhibitor, or any combination thereof.

17. 17. The pharmaceutical composition of claim 16, wherein the PD-1 pathway inhibitor comprises an anti-PD-1 antibody, an anti-PD-L1 antibody, a soluble PD-L2 polypeptide, and / or BMS-986189.

18. The anti-PD-1 antibody and / or anti-PD-L1 antibody is (a) is a full-length antibody; (b) is a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multispecific antibody; or (c) F(ab') ２ a fragment, a Fab' fragment, a Fab fragment, an Fv fragment, a scFv fragment, a dsFv fragment, a dAb fragment, or a single-chain binding polypeptide, 18. The pharmaceutical composition of claim 17.

19. The anti-PD-1 antibody (a) nivolumab, pembrolizumab, PDR001 (spartalizumab), MEDI-0680, TSR-042, cemiplimab, JS001, PF-06801591, BGB-A317, BI754091, INCSHR1210, GLS-010, AM-001, STI-1110, AGEN2034, MGA012, BCD-100, IBI308, SSI-361, or an antigen-binding portion thereof; (b) the CDR1, CDR2 and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO: 13, and the CDR1, CDR2 and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO: 14; (c) heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 15, 16, and 17, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs: 18, 19, and 20, respectively; (d) heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 13 and 14, respectively; or (e) heavy and light chains comprising the sequences set forth in SEQ ID NOs: 11 and 12, respectively; 18. The pharmaceutical composition of claim 17, comprising:

20. A pharmaceutical composition comprising an anti-LAG-3 antibody for use in combination with an anti-PD-1 antibody in treating relapsed or refractory classical Hodgkin lymphoma in a human subject, comprising: (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody Including, the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4; the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14; The subject is about 12 years of age or older and weighs about 40 kg or more. Pharmaceutical compositions.

21. The subject is (a) is under about 30 years of age, is under about 18 years of age, and / or is over about 16 years of age and has a Karnofsky performance score of 60 or greater; or (b) is about 16 years of age or younger and / or has a Lansky play performance score of 60 or greater; 21. The pharmaceutical composition of claim 20.

22. A pharmaceutical composition comprising an anti-LAG-3 antibody for use in combination with an anti-PD-1 antibody in treating relapsed or refractory classical Hodgkin lymphoma in a human subject, comprising: (a) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody Including, the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4; the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14; the subject weighs less than about 40 kg, is less than about 12 years old, or both; Pharmaceutical compositions.

23. 23. The pharmaceutical composition of claim 22, wherein the subject is about 16 years of age or younger and / or has a Lansky play performance score of 60 or greater.

24. A pharmaceutical composition comprising an anti-LAG-3 antibody for use in combination with an anti-PD-1 antibody in treating relapsed or refractory non-Hodgkin's lymphoma in a human subject, comprising: (a) about 160 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (b) about 80 mg of an anti-LAG-3 antibody and about 480 mg of an anti-PD-1 antibody; (c) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (d) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody Including, the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4; the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14; The subject is about 12 years of age or older and weighs about 40 kg or more. Pharmaceutical compositions.

25. The subject is (a) is under about 30 years of age, is under about 18 years of age, and / or is over about 16 years of age and has a Karnofsky performance score of 60 or greater; or (b) is about 16 years of age or younger and / or has a Lansky play performance score of 60 or greater; 25. The pharmaceutical composition of claim 24.

26. A pharmaceutical composition comprising an anti-LAG-3 antibody for use in combination with an anti-PD-1 antibody in treating relapsed or refractory non-Hodgkin's lymphoma in a human subject, comprising: (a) about 2 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody, or (b) about 1 mg / kg of an anti-LAG-3 antibody and about 6 mg / kg of an anti-PD-1 antibody Including, the anti-LAG-3 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:4; the anti-PD-1 antibody comprises CDR1, CDR2, and CDR3 domains of a heavy chain variable region having the sequence set forth in SEQ ID NO:13, and CDR1, CDR2, and CDR3 domains of a light chain variable region having the sequence set forth in SEQ ID NO:14; the subject weighs less than about 40 kg, is less than about 12 years old, or both; Pharmaceutical compositions.

27. 27. The pharmaceutical composition of claim 26, wherein the subject is about 16 years of age or younger and / or has a Lansky play performance score of 60 or greater.

28. (a) the anti-LAG-3 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs:5, 6, and 7, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs:8, 9, and 10, respectively; and the anti-PD-1 antibody comprises heavy chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs:15, 16, and 17, respectively, and light chain variable regions CDR1, CDR2, and CDR3 comprising the sequences set forth in SEQ ID NOs:18, 19, and 20, respectively; (b) the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 3 and 4, respectively, and the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 13 and 14, respectively; (c) the anti-LAG-3 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 1 and 2, respectively, and the anti-PD-1 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 11 and 12, respectively; (d) the anti-LAG-3 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 21 and 2, respectively, and the anti-PD-1 antibody comprises a heavy chain and a light chain comprising the sequences set forth in SEQ ID NOs: 11 and 12, respectively; or (e) the anti-LAG-3 antibody comprises BMS-986016 (leratolimab) and the anti-PD-1 antibody comprises nivolumab; 28. The pharmaceutical composition of any one of claims 20 to 27.